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CHAPTER I 
 
INTRODUCTION 
 
BACKGROUND 
Cardiovascular anatomy 
Mammals have a closed pressurized vascular system that is responsible for 
transporting nutrients to and removing waste products from every cell in the body. The 
vascular system has three major components: the heart, the arterial, and the venous 
systems. The arterial system begins proximal to the heart with the largest vessel in the 
body, the aorta. Distal to the aorta, each branch of the arterial system reduces diameter 
in a pattern described by Murray’s law [1, 2]. Murray’s law states that at any point in the 
circulation, blood flows through arteries whose radii cubed are summed to a constant 
value. Large arteries are highly elastic with three distinct layers: the intima, media, and 
adventitia. The intima, the innermost layer, consists of the vascular endothelium, a 
single layer of cells on top of a thin layer of basement membrane. The media is the next 
concentric layer and is comprised of alternating layers of smooth muscle and elastic 
lamina. The adventitia, the outermost layer, consists of connective tissue and is rich in 
fat. The adventitial also contains the vasa vasorum, which provides nutrients and 
oxygen to outer layers of large vessels, is innervated, and is home to resident immune 
cells. As arteries become smaller in more distal branches, they generally have fewer 
layers of elastic lamina, and become more contractile and less elastic. This is reflected 
by the requirements of Laplace’s law, which states that vessel wall thickness is 
2 
proportional to vessel radius at a constant pressure. Therefore, capillaries, the smallest 
arteries, may have only one or two cell layers to facilitate nutrient transport. The venous 
system is responsible for transporting deoxygenated blood back to the heart for re-
oxygenation in the pulmonary circulation. Postcapillary venules are the venous system 
corollary to capillaries, are largely responsible for immune infiltration into tissue and 
connect the venous system to the arterial system. The venous system operates at lower 
pressure and has thinner walls and higher compliance to match these requirements.  
The vascular endothelium 
Originally, endothelial cells were thought to be an inert barrier on the inside of blood 
vessels and lymphatics [3]. However, endothelial cells are diverse in phenotype and 
function and are master regulators of vascular homeostasis [4]. Endothelial cells are 
responsible for regulating vascular permeability to allow transport of nutrients into tissue 
and transport of waste away from tissue. Vascular permeability can be modulated by 
factors such as local inflammation and circulating factors such as lipoproteins. 
Endothelial cells are also responsible for regulating blood pressure and vascular tone in 
response to changes in cardiac output, for example as a response to exercise or stress. 
Endothelial cells release vasodilators such as nitric oxide (NO) and prostacyclin (PGI2) 
and vasoconstrictors such as endothelin (ET) and platelet activating factor [5].  
Endothelial cells also regulate the interaction of blood and blood cells with tissue. For 
example, endothelial cells are critical for hemostasis. Normally, endothelial cells are 
anticoagulant. However, in the case of injury or activation, endothelial cells become 
procoagulant by producing tissue factor, fibrinogen, and thrombomodulin regulating the 
coagulation of blood. In addition, endothelial cells are responsible for regulating 
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inflammation by recruiting leukocytes from the blood to fight infection in tissue. When 
injured, endothelial cells express selectins, cell adhesion molecules, and chemokines, 
which recruit immune cells into the vessel wall and promote proliferation of resident 
immune cells.  
Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of death in the developed world. In 
2015, 85.6 million American adults have at least one type of cardiovascular disease, 
and CVD is responsible for over 30% of deaths globally [6]. Hypertension is the most 
common form of CVD in adults, afflicting approximately 80 million adults in the US. 
While hypertension is the most common form of CVD, complications from 
atherosclerosis such as heart attack and stroke are responsible for the majority of CVD 
related deaths [6]. CVD is an enormous economic burden on the health care system, 
and costs are expected to rise as the incidence of diseases such as obesity and 
diabetes continues to increase. The risk factors that are currently recognized for CVD 
include family history and genetics, hyperlipidemia, hypertension, diabetes mellitus, 
metabolic syndrome, obesity, physical inactivity, nutrition, chronic kidney disease, and 
smoking. 
Atherosclerosis is a chronic disease of the vessel wall and predominantly forms in 
medium and large sized arteries. Atherosclerosis can develop from early in life 
beginning with, “fatty streaks,” which are purely inflammatory lesions rich in 
macrophages and T lymphocytes and are common in infants and young children [7]. At 
all stages, atherosclerosis can be considered a chronic inflammatory disease [8]. 
Starting with a response-to-injury hypothesis, an initial insult disrupts the normal 
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homeostatic properties of the vascular endothelium. The so-called, “dysfunctional 
endothelium,” initiates a series of events after damage, which can result in chronic 
inflammation and gradual development of atherosclerosis. Some examples of injurious 
stimuli include elevated cholesterol, specifically elevated low-density lipoprotein, 
increased free radicals, diabetes, elevated homocysteine, and bacterial or viral 
infection. These damaging stimuli lead to increased adhesiveness of the endothelium to 
platelets and immune cells and increased vascular permeability. At the onset of 
inflammation immune cells infiltrate and release chemokines and growth factors, 
causing smooth muscle cell proliferation and migration, which thickens the artery wall. 
In intermediate atherosclerotic lesions, this proliferation process is accompanied by 
outward remodeling so that the lumen remains patent. If inflammation persists, more 
cells migrate from the blood and proliferate in lesions, promoting smooth muscle 
proliferation, fibrous tissue formation and lipid accumulation. In advanced lesions the 
vessel can no longer outwardly remodel, resulting in narrowing or occlusion of the 
artery. 
Cardiovascular risk factors are associated with oxidative stress 
Oxidative stress is a major cause of endothelial dysfunction in diseases such as 
atherosclerosis, hypertension and diabetes [9, 10]. Oxidative stress is the 
overproduction of oxidants or reactive oxygen species (ROS) from the redox reaction of 
molecular oxygen to water. Examples include the free radicals superoxide, hydroxyl, 
nitric oxide and nonradicals such as hydrogen peroxide, peroxynitrite, and hypochlorous 
acid. Overproduction of these forms of ROS, specifically superoxide, can lead to the 
formation of other ROS by radical chain reactions, formation of damaging products such 
as lipid peroxides and oxidized proteins, activate pathological signaling pathways, and 
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further drive production of ROS by enzyme activation and expression (positive 
feedback). In the vasculature there are several enzymatic sources of ROS including 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, xanthine oxidase, 
cyclooxygenase, lipoxygenase, mitochondrial enzymes, P450 mono-oxygenase, and 
uncoupled nitric oxide synthase [11]. The three best studied enzymes responsible for 
oxidative stress in vascular disease are NADPH oxidases, xanthine oxidase, and 
uncoupled nitric oxide synthase.  
NADPH oxidases were originally identified in phagocytic cells such as neutrophils, 
however they are expressed in all tissues, and are important for many biological 
responses. NADPH oxidase has been identified as a major source of superoxide in 
vasculature. Cardiovascular risk factors cause increased expression and activity of 
NADPH oxidases. This has been validated in animal models of hypertension, diabetes, 
and atherosclerosis. Risk factors such as hypercholesterolemia are associated with 
increased activation of NADPH oxidases; for example, catalytic subunits Nox2 and 
Nox4 are overexpressed in atherosclerotic arteries. Xanthine oxidase is another 
potential source of superoxide and oxidant stress in cardiovascular disease, however 
there are conflicting reports of the impact of xanthine oxidase inhibitors such as purinol 
on development of cardiovascular disease [12]. These studies also show little evidence 
that other enzyme systems such as cyclooxegnase, or cytochrome P450 are 
pathologically important sources of superoxide.  
Nitric oxide synthase (NOS) 
NO is produced by a class of enzymes called nitric oxide synthases (NOS). There are 
three isoforms of NOS that share a common reaction mechanism to generate NO [13]. 
6 
NOS are modular enzymes that require dimerization to produce NO through a tightly 
regulated transfer of electrons. Each monomer of NOS has a C-terminal reductase 
domain and an N-terminal oxygenase domain. The C-terminal reductase domain of 
NOS binds to NADPH, flavin mononucleotide (FMN) and Flavin adenine dinucleotide 
(FAD) [13]. NOS monomers are linked together at the N-terminal oxygenase domains 
through a structurally important zinc-thiolate cluster [14]. The oxygenase domain also 
carries a prosthetic heme group and binds to the enzyme substrates, L-arginine, 
molecular oxygen (O2), and (6R-),6,7,8-tetrahydrobiopterin (BH4) [15-18]. In the 
functioning enzyme, an increase of intracellular calcium leads to calmodulin binding to 
NOS, which catalyzes electron transfer from NADPH and the flavins in the C-terminus 
reductase domain to the heme center where the electrons reduce O2 [19]. To produce 
NO, the enzyme cycles twice. The first cycle hydroxylates L-arginine to Nω-hydroxy-L-
arginine. In the second step NOS oxidizes the Nω-hydroxy-L-arginine to L-citrulline and 
NO [20].  
Role of nitric oxide (NO) in vascular disease 
NO was first identified as endothelium-derived relaxing factor in 1987 by Palmer et al. 
[21, 22]. In this role, NO causes blood vessel dilation by stimulating soluble guanylyl 
cylcase and increasing cyclic guanosine monophosphate in smooth muscle cells 
thereby reducing vasomotor tone [23, 24]. Aside from directly causing smooth muscle 
relaxation, NO has broad regulatory and signaling functions including suppressing 
inflammation, inhibiting platelet aggregation, reducing leukocyte adhesion to 
endothelium, and reducing smooth muscle cell proliferation [25, 26].  
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Almost all risk factors for cardiovascular disease have been shown to reduce vascular 
NO. Reduced bioavailability of NO could be due to decreased expression of NOS, 
decreased availability of NOS substrate L-arginine due to overexpression of arginases 
or oxidation, decreased NOS cofactors, increased NOS inhibitor asymmetric dimethyl-L-
arginine, and increased superoxide [27, 28]. Superoxide reacts with NO to form the 
strong oxidant peroxynitrite (OONO-) and eliminates the beneficial actions of NO [29, 
30]. This reaction is extremely avid, occurring a rate ten times faster than the enzyme 
superoxide dismutase converts superoxide to hydrogen peroxide (Km = 6.7 x 109, or 
nearly diffusion limited) [31, 32]. This means that NO production and availability is 
modulated by superoxide production, therefore the balance of the two is critical for 
vascular homeostasis. Reduced vascular NO is associated with dysfunction of 
homeostatic signaling pathways, leading to vascular disease. Notably, this effect cannot 
be rescued by increasing enzymatic production of NO, or supplementation with 
nitrovasodilators, which raise systemic NO [33, 34]. In the United States, there are two 
classes of nitrovasodilators used, organic nitrates such as nitroglycerin, and 
nitroprusside [35]. A primary concern of use of these drugs is the development of nitrate 
tolerance, which leaves patients vulnerable to acute ischemia [36]. Also, Long term 
treatment with nitrovasodilators is associated with endothelial dysfunction and 
overproduction of superoxide by the endothelium of tolerant vessels, leading to the 
breakdown of NO and other deleterious effects [37-39]. Consequently, systemic 
administration of nitrovasodilators has led to worsened prognosis for patients with 
coronary artery atherosclerosis [37]. The harmful result of NO supplementation is likely 
due to the avid reaction of NO with superoxide forming ONOO- [29]. Therefore, it is of 
greater facility to focus therapies on reducing superoxide rather than donating excess 
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nitric oxide. Another proposed mechanism for nitric oxide’s contribution to oxidative 
stress in cardiovascular disease is dysfunction of the enzyme that produces NO [40]. 
Production of ROS by NOS 
Studies with hypertensive mice demonstrated that treatment with NOS inhibitor NG-
nitro-L-arginine reduced oxidative stress in vessels, demonstrating a significant 
contribution of the NOS enzymes to oxidative stress in vascular disease [41]. In the 
absence of enzyme substrate L-arginine or the cofactor BH4, the flow of electrons in 
NOS is disrupted and the oxygenase domain of NOS produces superoxide instead of 
NO [42-44]. This is called NOS uncoupling. NOS uncoupling is a primary candidate for 
vascular ROS production and therefore oxidative stress in vascular disease [28, 45, 46]. 
NOS uncoupling has been observed in cells treated with low-density lipoprotein (LDL), 
cells treated with peroxynitrite and vessels from animals experimentally induced 
hypertension and diabetes [27, 47, 48]. NOS uncoupling has also been observed in 
patients with diabetes, hypertension, hypercholesterolemia, and in chronic smokers [49-
52]. There are several mechanisms by which NOS can become uncoupled. One 
explanation could be deficiency of the enzyme substrate L-arginine. However, L-
arginine levels are normally several times higher than the Michaelis constant of the 
NOS enzyme, cells can recycle L-citrulline to L-arginine, and obtain L-arginine from 
breakdown of proteins in the urea cycle, and supplementation with L-arginine does not 
decrease NOS uncoupling [53]. In association with low levels of L-arginine, the 
presence of dimethyl-L-arginine could also inhibit the NOS enzyme and reduce 
availability of NO [54, 55]. However, elevated dimethyl-L-arginine levels are more likely 
to be a result of elevated ROS rather than a cause. Another explanation for NOS 
uncoupling and production of ROS in disease is that NOS monomers are unable to form 
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dimers. However, the efficiency of electron transfer by NADPH is much higher in NOS 
dimers, therefore dissociated NOS monomers are unlikely to be a significant source of 
ROS [56].  
A major cause for NOS uncoupling is reduced concentration of the cofactor BH4 [28, 57, 
58]. Studies have demonstrated that reduced intracellular BH4 correlates directly with 
NOS dysfunction. BH4 level depends on the balance of production and oxidation of 
pterins [59]. Because BH4 is one of the most potent naturally occurring reducing agents, 
it is readily oxidized to inactive forms such as dihydrobiopterin (BH2). Therefore, 
oxidative stress may result in the excessive oxidation of BH4 and reduction of the 
availability of the cofactor. Reduced BH4 has been reported in animal models of 
cardiovascular disease, and in human patients with cardiovascular disease [60, 61]. In 
addition, supplementation of BH4 has been shown to reduce production of superoxide 
by NOS, suggesting that BH4 plays the central role in NOS uncoupling [48-50, 52, 53, 
62].  
Production of radicals by xanthane oxidase, NADPH oxidase, mitochondrial electron 
transport, and uncoupled NOS in response to pathological stimuli can be “kindling” 
radicals. These radicals oxidize or modify other enzymes, leading to an increase in ROS 
formation by these other enzymes or “bonfire” radicals. Many examples exist in the 
literature of this interaction [63, 64]. 
Hemodynamics 
The vascular system is constantly exposed to hemodynamic mechanical stimulation. 
During each cardiac cycle, blood pressure fluctuates and causes pulsatile fluid flow and 
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cyclic expansion of blood vessels. The propagation of this pressure wave exerts both 
hoop stress and fluid shear stress on blood vessels. 
 
Figure 1. Hemodynamic forces acting on the vasculature. The two major stresses are 
hoop stress from cyclic changes in blood pressure, and shear stress, the tangential 
frictional force of blood flowing across the vascular wall. Figure adapted from Hahn et. 
al. [65]. 
Fluid shear stress a force tangential to the inner surface of the blood vessel caused by 
viscous drag from fluid flow. Fluid shear stress at the endothelium is loosely 
approximated by modeling blood as a Newtonian fluid flowing through a straight rigid 
pipe of constant diameter using Poiseuille’s law derived from the Navier-Stokes 
equations. This model describes a parabolic flow profile, where the maximum velocity of 
fluid flow is in the center of the channel, and the velocity at the wall is zero (no slip 
condition). The gradient of fluid velocity in the radial dimension is the fluid shear stress, 
and is approximated by the Hagen-Poiseuille equation (Figure 2). Poiseuille’s law is 
dependent on laminar flow, and the Reynolds number of the system can be used to 
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approximate the presence of laminar flow. The Reynolds number is defined as the ratio 
between the inertial forces and viscous forces in the system and is dependent on the 
mean velocity of fluid flow, the kinematic viscosity, and the length scale of the system 
(the diameter for a pipe). In Poiseuille flow in a straight pipe, transition from laminar to 
turbulent flow occurs at Reynolds numbers above 2040 [66]. 
𝑹𝒆 =  
𝒊𝒏𝒆𝒓𝒕𝒊𝒂𝒍 𝒇𝒐𝒓𝒄𝒆𝒔
𝒗𝒊𝒔𝒄𝒐𝒖𝒔 𝒇𝒐𝒓𝒄𝒆𝒔
=
𝝆𝒗𝑳
𝜼
,  
𝒘𝒉𝒆𝒓𝒆: 𝝆 = 𝒅𝒆𝒏𝒔𝒊𝒕𝒚, 𝒗 = 𝒎𝒆𝒂𝒏 𝒗𝒆𝒍𝒐𝒄𝒊𝒕𝒚, 𝑳 = 𝒄𝒉𝒂𝒓𝒂𝒄𝒕𝒆𝒓𝒊𝒔𝒕𝒊𝒄 𝒍𝒆𝒏𝒈𝒕𝒉, 𝜼 =
𝒅𝒚𝒏𝒂𝒎𝒊𝒄 𝒗𝒊𝒔𝒄𝒐𝒔𝒊𝒕𝒚  
 
Figure 2. Reynolds number and Fluid shear stress calculated assuming Hagen-
Poiseuille flow in a rigid pipe. 
There are many factors that lead to disruption of laminar flow in vivo. Blood is a 
heterogeneous, multicomponent, thixotropic non-Newtonian fluid. Shear thinning 
behavior means that blood viscosity is least during peak systole, and greatest during 
peak diastole. In addition, blood vessels are not rigid but distensible; flow rate varies 
with cardiac cycle and arterial geometry changes rapidly. 
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Arterial geometry affects the blood flow pattern in the cardiovascular system. In straight, 
un-branched vascular segments blood flow is approximately unidirectional and laminar 
and time average fluid shear stress is high. At branch points, sites of curvature and 
distal to stenoses blood flow becomes disturbed. Such regions can display flow 
separation, vortical shedding and low and oscillatory fluid shear stresses [67]. These 
phenomena are indicative of transition from laminar flow to turbulent flow and 
breakdown of the Poiseuille model. Transition away from laminar flow is induced by 
changes in geometry. This is observed with Newtonian fluids in models of the human 
carotid bulb where Reynolds number is as low as 400. An example of this phenomenon 
at Reynolds number 800 is depicted below. 
 
Figure 3. Glass model of blood flow in the human carotid artery bulb. This image was 
captured by Zarins et al. by modeling a human carotid artery bulb in glass, and flowing 
hydrogen bubbles in a viscous solution to visualize flow patterns [68]. This 
demonstrates the formation of disturbed flow in response to arterial geometry. 
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In vitro and in vivo models for studying shear stress 
To study the effects of variations in blood flow, model systems are required that 
recapitulate the flow patterns observed in these naturally occurring locations of altered 
flow. In vitro models are useful because they allow a reductionist approach that 
eliminates variables such as the non-Newtonian nature of blood and unpredictable 
changes in geometry. There are several useful in vitro models for the study of the 
effects of altered shear stress on cellular phenotype [69]. Cone-in-plate cell culture, 
pioneered by C. Forbes Dewey, has become a well-established method to subject living 
cells to fluid shear stress [70, 71]. The system works in much the same manner as a 
cone-in-plate viscometer, were cells can be cultured in a dish, and fluid flow induced by 
rotating a cone in the culture media above the cells. This system makes it possible to 
recapitulate either laminar unidirectional fluid shear stress or oscillatory fluid shear 
stress at physiologically relevant fluid shear stresses. However, due to the length scale 
of the device, and the use of culture media that is more similar to a Newtonian fluid, 
these devices are unlikely to achieve disturbed flows as observed in vivo. Another 
common approach for in vitro cell culture under fluid shear conditions is a parallel plate 
flow chamber. In this apparatus, cells are grown in a rectangular channel, and flow is 
provided either by hydrostatic pressure, or by pumps. These systems are also capable 
of achieving laminar unidirectional flow, as well as oscillatory flow, but are subject to the 
same limitations imposed by Reynolds number and transition to turbulent flow.  
In vivo models are more likely to accurately capture dynamics of the complex variations 
in blood flow patterns. One option for studying variations in fluid shear stress is to 
simply observe locations that are known to develop disturbed flow such as the branches 
of the coronary arteries, where the iliac arteries branch from the distal aorta, and where 
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the aorta curves sharply proximal to the heart. There are also in vivo models available 
that can recapitulate variations in shear in a more controlled manner. A first example is 
the implantation of perivascular cuffs that can constrict arteries creating a sort of 
artificial stenosis [72, 73]. Rapid changes in geometry such as constrictions result in 
development of disturbed flow downstream of the restriction. This model is best suited 
for use in larger animals, and its limited utility in murine models prone to atherosclerosis 
prompted the more recent development of the murine partial carotid artery ligation 
model. In this model, three of the four ascending branches of the left carotid artery are 
surgically ligated. With each cardiac cycle, blood flows up the common carotid artery 
and encounters resistance from the ligations causing retrograde flow [74]. This leads to 
the rapid formation of advanced atherosclerotic lesions in mice prone to develop 
atherosclerosis [74]. Both of these models create flow patterns that are characteristic of 
disturbed flow observed pathophysiological sites. 
Endothelial mecahnotransduction 
The vascular endothelium is in direct contact with flowing blood and displays 
remarkable plasticity in response varying fluid shear stresses [75]. Endothelial response 
to fluid shear stress is likely an adaptive mechanism designed to maintain sufficient 
blood flow to body tissues. For example, fluid shear stress acutely regulates blood 
vessel diameter by maintaining endothelial signaling for smooth muscle cell relaxation 
by nitric oxide production, prostacyclin, and arachidonic acid [25, 26, 76]. These 
changes serve to normalize fluid shear stress in response to sudden increases in 
cardiac output, for example during exercise [77, 78]. Over time, increased flow can 
result in permanent vascular remodeling [79-81]. It is interesting to note that the cyclic 
hoop stress on endothelial cells from oscillating pressure is four orders of magnitude 
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larger than the fluid shear stress from blood flow, but shear stress is still believed to be 
the major determinant of endothelial response [82]. 
There are numerous proposed mechanisms for mecahnotransduction of fluid shear 
stress in endothelial cells. For example, endothelial cells may sense forces and 
transduce them to downstream chemical signals through the cytoskeleton, ion channels, 
integrins, receptor tyrosine kinases, primary cilia, the apical glycocalyx, heterodymeric 
guanine nucleotide binding proteins (G proteins), and caveolins. The cytoskeleton is 
responsible for maintaining the shape and morphology of endothelial cells, and plays 
important roles in cellular response to forces [83-86]. The cytoskeleton has several 
components: actin, microtubules, and intermediate filaments. In experiments studying 
mecahnotransduction, pharmacological or genetic inhibition of cytoskeletal components 
block endothelial responses to shear [87-89]. However, there is little evidence that 
suggests that the cytoskeleton is solely responsible for transduction of shear stress. 
Some putative mechanosensors reside on the cell surface and are in direct contact with 
flowing blood making them logical candidates for transduction of fluid shear signals. For 
example, fluid shear modulates the fluidity of cell membranes, which could implicate 
caveolins or other membrane components [90-94]. In addition, changes in membrane 
fluidity affect the activity of G proteins, which could be involved in flow sensing in either 
ligand dependent or independent roles [95-98]. Considering the profound effects of 
changes in intracellular potassium and calcium on downstream signals associated with 
shear sensing, mechanosensitive ion channels are also implicated as 
mechanotransducers [99-102]. In addition, these channels can control the release of 
adenosine triphosphate (ATP) and ATP synthesis [103-108]. Also present on the 
surface of endothelial cells is a dense glycocalyx [109-111]. This covering of 
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proteoglycans may protect the actual cell membrane surface from directly experiencing 
shear from flowing blood, and suggests that force may be transmitted through the 
glycocalyx [112-114]. Some studies have shown that digestion of proteoglycans blunts 
response to shear, however it is unclear if this is due to disruption of the apical 
glycocalyx or the basal lamina, which would affect integrin signaling through 
extracellular matrix (ECM) proteins [115, 116]. Endothelial cells also express primary 
cilia, and genetic deletion of primary cilia protein results in vascular defects in mice 
[117-119]. However, their role in fluid shear sensing in vivo is unclear, although they 
may be responsible for sensing low levels of fluid shear stress [120-122].  
The major mechanosensing mechanism is likely receptors between cells, namely a 
three-protein complex of platelet endothelial cell adhesion molecule-1 (PECAM1), 
vascular endothelial (VE)-cadherin, and vascular endothelial growth factor receptor 2 
(VEGFR2) [123]. Within this complex, increased tension on PECAM1 leads to the 
activation of a Src family kinase which acts on VEGFR2 to recruit and activate 
Phosphoinositide 3-kinase (PI3K) by a ligand independent receptor activation process. 
PI3K activation is the effector of downstream shear stress activation including NOS 
phosphorylation and increased integrin recruitment. VE-cadherin appears to mediate 
VEGFR2 association with PECAM1 [25]. While this integrin mediated signaling is 
responsible for downstream endothelial activation, the upstream activator of PECAM1 in 
response to shear stress is still unclear. The role of cyclic hoop stress in endothelial 
mecahnotransduction is also unclear, as it is impossible to decouple the two 
phenomenon in vivo. 
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Endothelial response to shear stress waveforms 
In the setting of unidirectional laminar fluid shear stress, endothelial cells elongate and 
align in the direction of flow and develop an anti-inflammatory and anti-thrombotic 
phenotype [65]. These effects are associated with acute changes in endothelial cell 
signaling and marked changes in gene expression over the long term [75, 124]. As 
examples, in response to laminar shear endothelial cells increase NO and prostacyclin 
production, increase mRNA and protein expression of kruppel like factor 4 and 
endothelial nitric oxide synthase (eNOS), and exhibit decreases in inflammatory 
mediators such as nuclear factor kappa light chain enhancer of activated B cells (NF𝛋B) 
and adhesion molecules [10].  
In striking contrast, endothelial cells exposed to disturbed flow do not align and 
elongate, and become pro-inflammatory and pro-thrombotic. Disturbed flow causes the 
same transient changes in endothelial cells, however, exposure to disturbed flow is 
associated with sustained activation of pro-inflammatory signals such as NFκB, JUN N-
terminal kinase, p21-activated kinase, and increased expression of inflammatory 
mediators including vascular cell adhesion molecule-1, intracellular adhesion molecule-
1 and chemokines such as the monocyte chemoattractant peptide-1 [65, 74, 125-127].  
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Figure 4. Shear stress waveforms measured by MRI in healthy human patients 
corresponding to atheroprotective and atheroprone flow adapted from Dai et al. [128]. 
Endothelial morphology changes when exposed to atheroprotective versus atheroprone 
fluid shear waveforms. 
Focal Development of atherosclerosis 
The changes in endothelial cell phenotype caused by disturbed flow predispose these 
regions to local lipid deposition, inflammation and the focal development of 
atherosclerosis. This is exemplified by the fact that endothelial function nearly directly 
correlates with risk factor profiles [48]. In a seminal paper, Ku et al. observed that 
atherosclerosis correlates with sites of disturbed flow in vivo [67]. Atherosclerotic lesions 
predominantly occur at sites known to have disturbed flow such as branch points, the 
proximal coronary arteries and the distal aorta [48, 125, 126].  
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Effect of shear stress profiles on vascular NO 
The most abundant source of NO in vasculature is the endothelial NOS isoform (eNOS). 
When exposed to atheroprotective shear stress, in vitro there is a transient increase in 
intracellular calcium in endothelial cells, which causes calmodulin binding to eNOS and 
increases eNOS activity [129]. Simultaneously, phosphorylation by protein kinase B 
increases eNOS activity [130-133]. Over the course of several hours, shear stress 
causes an increase in eNOS protein, mRNA, and mRNA stability through the canonical 
MAP kinase pathway [10, 126]. eNOS transcription is increased by NFκB binding to the 
eNOS promoter [134]. After this acute effect, increased NO inhibits NFκB by 
nitrosylation of p50, decreasing activation of pro-inflammatory pathways, and returning 
eNOS transcription to the basal rate [135, 136]. In addition to increasing eNOS 
production and activity, atheroprotective flow also increases production of reactive 
oxygen species through NADPH oxidase, which is balanced by increased expression of 
enzymes that scavenge harmful ROS such as Cu/Zn superoxide dismutase (SOD), 
extracellular SOD, and glutathione peroxidase [137-142].  
Tetrahydrobiopterin (BH4) and atherosclerosis 
It has been shown that a major source of reactive oxygen species in endothelial cells 
exposed to disturbed flow is uncoupled eNOS [28]. Oscillatory fluid shear stress on 
endothelial cells results in an uncoupling of the eNOS enzyme. The mechanism of 
oscillatory fluid shear stress induced eNOS uncoupling is a combination of fluid shear 
effects on production of BH4 and destruction of BH4 by increased oxidative stress. Three 
enzymes coordinate the de-novo synthesis of BH4. First, Guanosine-5’-triphosphate 
cyclohydrolase 1 (GTPCH-1), cleaves GTP to 7,8-dihydroneopterin triphosphate. Next, 
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6-pyruvoyl-tetrahydropterin synthase (PTPS) converts 7,8-dihydroneopterin 
triphosphate to 6-pyruvoyl-tetrahydropterin. In a final NADPH-dependent step 
sepiapterin reductase (SR) reduces 6-pyruvoyl-tetrahydropterin to BH4. GTPCH-1 is the 
rate-limiting enzyme in the de-novo synthesis pathway of BH4. Hydrogen peroxide 
stimulation can lead to an upregulation of GHPCH-1 protein levels, and increased BH4 
production [143-145]. Laminar shear causes a 2 fold increase GTPCH-1 
phosphorylation at serine 81 by the α’ subunit of casein kinase 2 (CK2) and increases 
its activity 30 fold compared to static culture in vitro [33, 127]. Shear stress does not 
regulate PTPS or SR, and does not change the protein levels of GTPCH-1, PTPS, SR, 
or CK2, indicating that shear stress regulates BH4 synthesis by phosphorylation of 
GTPCH-1. BH4 oxidation to inactive BH2 is also increased in disturbed flow due to 
oxidative stress, which further depletes intracellular stocks of BH4. While stocks of the 
critical cofactor are depleted, electron transfer from NADPH continues to form the 
heme-oxygen intermediate at the oxygenase domain prosthetic heme group of the NOS 
enzyme. However, without BH4 to reduce the heme-oxygen intermediate NOS is not 
coupled to L-arginine and therefore produces superoxide rather than NO.  
Need for targeted cardiovascular disease treatments 
Most of the current treatments for atherosclerosis focus treatment of systemic risk 
factors. However, none of these therapies completely prevent cardiovascular events 
resulting from atherosclerosis. As an example, HMG Co-A reductase inhibitors reduce 
cardiovascular events by approximately 40 to 50% indicating that there are residual 
risks that persist after lipid lowering [146, 147]. This outcome indicates that there may 
be additional, underappreciated risk factors of cardiovascular disease that are not 
addressed with current therapies. One explanation for this residual risk is that current 
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treatments do not specifically target atheroprone vasculature. Such regions might 
require a high local concentration of drug not achieved by systemic administration.  
A common complication of atherosclerosis is thrombosis. Systemic administration of 
antithrombotic drugs increases the risk for hemorrhage. Fibrinolytic drugs such as 
streptokinase and tissue plasminogen activator are inactivated rapidly in plasma and 
may fail to reach effective concentrations [148-151]. Targeted administration of 
antithrombotic treatments is an example of the need for targeted cardiovascular disease 
treatments [152]. However, the focus of this thesis is prevention of atherosclerosis, and 
thrombosis is an end stage complication of atherosclerosis.  
Other therapeutic approaches target oxidative stress in cardiovascular disease. For 
example, supplementation with exogenous BH4 can rescue the uncoupled state of 
eNOS and prevent atherosclerosis in experimental animals [153]. However, there are 
barriers to using BH4 as a therapeutic for cardiovascular disease. Major challenges 
associated with delivery of exogenous BH4 include oxidation and poor cellular uptake in 
endothelial and parenchymal cells [62]. While already oxidized forms of BH4 such as 
BH2 have better pharmacokinetics, the salvage pathway that converts BH2 to BH4 is 
downregulated where fluid shear stress is oscillatory [127]. This potentially negates the 
benefit of delivering BH2 to atheroprone endothelium. In addition, BH4 is also a cofactor 
for the synthesis of catecholamines, which could lead to unanticipated neurological 
effects if the co-factor is not delivered in a targeted fashion [33]. Nanomedicine is an 
attractive platform for targeting cardiovascular disease therapies such as BH4, anti-
inflammatory drugs, statins, and antithrombotic therapies to regions of the circulation at 
risk for atherosclerosis 
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Nanomedicine 
Nanomaterials are of particular interest for drug delivery because they offer advantages 
over traditional molecular drugs [154]. For instance, nanomaterials can be used to 
extend drug activity, deliver drugs to specific cells or tissues, deliver poorly soluble 
drugs, facilitate imaging and drug delivery simultaneously, deliver multiple therapeutics 
simultaneously, deliver macromolecular drugs, and bypass delivery barriers [154, 155]. 
Nanomedicine is also ideal for targeted intravascular drug delivery. Several nanoparticle 
approaches have been explored for cardiovascular disease diagnosis and therapy. 
Examples include polymer micelles, polymer nanospheres, ultrasound-sensitive 
materials such as nano and microbubbles, gold nanoparticles such as rods and shells, 
polymer dendrimers, quantum dots, magnetically sensitive nanoparticles such as 
ultrasmall superparamagnetic iron oxides (USPIOs), radiolabeled particles, and 
naturally occurring nanoparticles such as high density lipoprotein. However, the best-
studied nanoparticle for vascular delivery applications is the liposome.  
Liposomes for drug delivery 
Liposomes were the first nanotechnology drug delivery platform and were developed in 
the 1960s [156]. Liposome formulations are diverse and flexible. The most basic 
characterization of liposomes is based on their size, surface charge, and lamellarity 
(number of layers). Basic classifications of liposomes are uni- or multi-lamellar, small 
(<100 nm), intermediate (100 – 250 nm), large (> 250nm), and either cationic, anionic, 
or neutral charge [157]. Since their inception, liposomes have been widely used due to 
their biocompatibility, ease of use, versatility and facile chemistry. Liposomes can 
encapsulate hydrophilic, hydrophobic and amphiphilic drugs, and there are numerous 
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lipid modifications available with different physical and chemical characteristics. 
Because of the versatility of chemistries available, liposomes are generally considered 
to be more easily scalable for production. In addition, the lipids used to form liposomes 
are of natural origin and are therefore inherently biocompatible, and limit the toxic 
effects that can be encountered with synthetic nanoparticles.  
Nanotherapeutic targeting 
The first targeted liposomes were developed in the early 1980s [158, 159]. 
Nanomedicine has been applied most often to the fields of cancer and vascular 
pathologies. Targeting is highly important for these fields due to the focal nature of both 
diseases, and the need for high local concentrations of drugs of effectively combat the 
pathologies. Particularly in the field of cancer therapies, there is a significant effort to 
use nanomaterials that are targeted to tumor sites to reduce off target potentially toxic 
effects of cytotoxic drugs and increase concentrations in tumor cells.  
Passive targeting 
The most common method to achieve targeted drug delivery is passive targeting to 
tumors through the enhanced permeability and retention effect (EPR) [160]. This is 
achieved by nanoparticle-encapsulated drugs passively extravasating through leaky 
vasculature and the irregular lymphatic system of tumors. The EPR method relies on 
tuning the size, charge, and circulation time of nanoparticles to optimize uptake in 
permeable tissues. A common method to increase circulation time is addition of a highly 
hydrophilic corona, usually by conjugation with a polymer such as poly(ethylene glycol) 
(PEG). PEG also serves to shield the surface charge of cationic nanoparticles, for 
example those used to condense negatively charged DNA. While this effectively 
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increases circulation half-life of these drugs, and therefore improves passive targeting, 
disadvantages of using PEGylation include changes in pharmacokinetic behavior, 
immunological reactions, biodegradability, and toxicity of degradation products [161]. 
PEGylated nanoparticles have increased the incidence of stomatitis in clinical trials 
[157]. Tailoring the surface charge of nanoparticles can further enhance passive 
targeting. For example, inclusion of positive charge in the nanoparticle corona can 
enhance targeting to tumor vasculature [162]. While there are some reports of 
increased permeability in the setting of cardiovascular disease, specifically targeted 
approaches are more attractive for diagnosis and treatment of cardiovascular disease 
with nanoparticles.  
Targeting nanomaterials to vascular disease sites 
The molecular mechanisms of vascular disease both necessitate and provide exciting 
opportunities for disease site specific targeting of nanomaterials. Nanoparticles can be 
functionalized to home to specific vascular regions affected by inflammation, 
thrombosis, lipid accumulation or oxidative injury. Table 1 shows a list of targeting 
strategies that have been employed to target nanomaterials to sites of vascular disease. 
Table 1. Potential targets for cardiovascular disease nanotherapeutics. 
Target  Cell/mechanisms targeted 
VCAM Endothelial cells 
ICAM Endothelial cells 
PECAM Endothelial cells 
E-Selectin Endothelial cells 
P-Selectin Endothelial cells/ platelets 
L-Selectin Endothelial cells 
Integrin αVβ3 Platelets 
Integrin GPIIb-IIIa Platelets 
Integrin GPIa-IIa Platelets 
Integrin GPVI Platelets 
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Integrin GPIb-IX-V Platelets 
Scavenger Receptors Macrophages 
Oxidized LDL receptors Macrophages 
Lipoproteins Hyperlipidemia 
Annexins Coagulation/ inflammation 
Fibrin Coagulation 
Collagen Coagulation/ tissue remodeling 
MMPs Tissue remodeling 
Tissue factor Coagulation  
 
Liposomes in cardiovascular disease targeting 
Liposomes have been studied extensively utilizing the potential targets listed in table 1. 
By far the most common targets for liposomes and other nanomaterials are cell 
adhesion molecules such as PECAM, ICAM-1, and VCAM-1 [155]. Liposomes 
functionalized with anti VCAM-1 antibodies have been used for imaging and to deliver 
prostaglandins to lesion sites [163]. Liposomes decorated with anti-ICAM-1 antibodies 
have been used to deliver ultrasound contrast enhancement to sites of atheroma [164]. 
Liposomes have also been utilized for anti-thrombotic treatments by targeting to 
platelets through surface receptors such as P-selectin and integrin BPIIb-IIIa and RGD 
peptides [165, 166]. Several thrombolytic approaches have also relied on nonspecific 
uptake at areas of clotting [167, 168]. Another targeting approach for molecular imaging 
of atherosclerosis is indirectly targeting lesions through macrophages. Adding charged 
membrane components such as phosphatidylserine and decadeoxyguanine to the 
liposomes induces uptake in macrophages through scavenger receptors [169-172]. 
Shortcomings of current targeting strategies 
While there are clinically approved nanomedicines, most notably liposome-
encapsulated doxorubicin; in the 35 years since the development of the first targeted 
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nanotherapy none have made a significant impact through clinical translation [154, 173]. 
The reasons for failure are complex, but a primary concern is a need for new effective 
biomarkers for disease that allow targeted drug delivery on the correct spatiotemporal 
scales with minimal off target affects. Previously, nanoparticles have been used that 
target inflamed endothelium, inflammatory cells, the low-density lipoprotein receptor, 
thrombi and platelet aggregates [174-181]. While these studies have set a precedent for 
nanoparticle delivery to atherosclerosis, they depend on molecular determinants of 
lesions preset after the initiation of the disease. These studies target mature lesions, 
which implies that these targeting methods cannot be applied prophylactically. In 
addition, current approaches focus on molecular targets that are known to be up-
regulated in atherosclerotic regions. At this point, positive feedback processes are 
established and reversal of the disease may be impossible. Therefore, new approaches 
are needed which can target atherosclerosis at its earliest stages and prevent the 
development of the disease. To accomplish this, novel biomarkers targeting disturbed 
flow are needed. My thesis work sought to discover novel ligands that target 
atheroprone flow as the first event that initiates atherosclerosis. 
Phage display is a tool to develop targeting strategies for nanomedicine 
Phage display is a powerful combinatorial method that can be used to screen and 
engineer polypeptides, antibodies, and antibody fragments that bind to virtually any 
target. This technique is particularly useful for nanomedicine, because it allows the 
discovery of ligands that can be conjugated to the surface of nanoparticles and used for 
targeting. Peptide phage libraries are ideal for nanomedicine applications because the 
peptides discovered are generally low molecular weight, are easily synthesized, are 
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degraded to biocompatible byproducts in vivo, and generally elicit less inflammatory 
response than antibodies [182].  
Bacteriophages are viruses that specifically infect bacteria and are one of the simplest 
“living” organisms. They were first hypothesized to exist by Max Delbrück in the 1930s 
[183]. Phage display was first described using the Escherichia coli- specific 
bacteriophage M13 in 1985 [184]. Since this discovery, other phage systems including 
λ-phage T4 phage, and eukaryotic viruses have been employed, however the M13 
bacteriophage system is most popular. The M13 phage is a filamentous viral particle 
approximately 1 µm long and less than 10 nm in diameter consisting of a single 
stranded DNA core surrounded by five coat proteins (Figure 5) [185]. The major coat 
protein, protein P-8, covers the majority of each phage particle. The P3, P6, P7 and P9 
coat proteins cover the ends of the phage particle, and 5 copies of each are displayed 
per phage particle. The P3 coat protein is the most complex, and is involved in 
bacteriophage recognition of the F-pilus of E. coli [186].  
 
Figure 5. Structure of an M13 bacteriophage phage displayed library. Fusion peptides 
are attached at the N terminus of all five copies of the P3 coat protein Adapted from 
[185]. 
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Phage libraries are constructed by inserting random mutations that encode peptide 
sequences into the coat protein genes of bacteriophages [187]. When the phage is 
produced in the bacteria, the inserted proteins are displayed in the coat of the 
bacteriophage. The first generation of random peptide libraries was demonstrated in the 
late 1980s [188]. Today, the most common phage libraries in use are N-terminal fusions 
to the P3 coat protein of M13 and phage libraries are readily commercially available. 
The most important advantage of using phage libraries is that the displayed peptides 
are directly linked to the DNA sequence of the phage they are displayed on. Practically, 
this means that peptides selected from phage screening can be readily identified by 
replication of the viral particle and sequencing of the inserted nucleic acid sequence. 
The advantages of being able to use standardized biochemical techniques are offset by 
the possibility for random mutation of the fusion peptide or that the fusion peptide could 
be fatal to phage replication. This could result in limited diversity of polypeptide display. 
For example, it is well known that arginine causes a secY-dependent secretion of the 
PIII, which reduces peptides containing arginine. This is corrected by addition of prlA 
suppressors during bacterial growth [189]. In spite of these shortcomings, phage 
libraries are available that represent 1012 fusion peptides with unique amino acid 
sequences [186].  
Phage display is used to identify phage clones that bind to a target in a highly specific 
manner, a process called phage panning. A strength of this technology is that it can 
identify interactive regions of proteins and other molecules without pre-existing 
knowledge about the nature of the interaction. The simplest application of this process 
involves identifying a target and screening phage against the isolated target. In this 
process the phage library is allowed to interact with the desired target. Nonbinding 
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phage are washed away and binding phage are amplified and re-used in a serial 
refinement process (Figure 6).  
 
Figure 6. Phage display panning process. Step 1 is introduction of the phage library to 
a target immobilized on a plate. Step 2 is washing of the plate to remove unbound 
phage. Step 3 is eluting the bound phage and amplifying the clones recovered for the 
next round of panning. 
More complex phage panning strategies have been employed to determine biomarkers 
with the ultimate goal of developing targeted drug delivery systems. Pasqualini and 
Ruoslahti were the first to report using phage display in vivo to identify fusion peptides 
that targeted whole organs such as the brain and kidneys [190]. They later showed that 
organ-specific targeting can be accomplished by leveraging the heterogeneity of the 
vascular endothelium [191, 192]. Endothelial heterogeneity is well suited for discovering 
peptides that mediate targeting to cardiovascular disease, particularly for targeting 
intravenous nanoparticle delivery. 
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Three distinct approaches have been used to find ligands for nanoparticle targeting. 
These include targeted in vitro phage display based on previously identified molecular 
targets such as cell adhesion molecules, screening against cell surfaces and screening 
against atherosclerosis in vivo [192-194]. The first approach is particularly useful when 
high-value targets have been identified by methods such as gene arrays, but structure-
function relationships are unclear and preclude design of targeting ligands. In this 
context, phage display has been used to identify binding partners for diverse targets 
including the compliment system, integrins, caspases, metalloproteinases, cell adhesion 
molecules and glycoproteins [192, 195]. However, the reductionist strategy of isolating 
specific cell receptors or molecular targets does not necessarily capture their display in 
vivo, or guarantee that they are the most useful for targeting of nanotherapeutics. 
Therefore, approaches two and three are considered more useful for translational 
research in nanoparticle targeting.  
In the context of atherosclerosis, there have been several efforts to use phage display 
to identify ligands that target molecular determinates of the disease. Thapa, et al., found 
peptides that home to activated endothelial cells in atherosclerotic plaques in low 
density lipoprotein knockout mice using in vitro panning against tumor necrosis factor 
alpha treated bovine aortic endothelial cells [196]. Hong, et al., used phage panning 
against human atherosclerotic tissue ex vivo to identify peptides binging to interleukin 4 
receptor [197]. Kelly, et al., used phage screening against cells overexpressing VCAM-1 
to identify peptides with homology to very late antigen 4 that target VCAM-1 
overexpressing cells [179]. They demonstrated homing of nanoparticles functionalized 
with these peptides to sites of induced inflammation in vivo. Using in vivo phage 
screening in Apolipoprotein (Apo) E deficient mice Kelly, et al., identified several 
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families of peptides binding to leukemia inhibitory factor receptor, transferrin receptor 
and VCAM-1 [178]. Using in vivo phage display, Liu, et al., identified peptides that that 
mediate homing to mature atherosclerotic lesions in apolipoprotein E knockout (ApoE-/-) 
mice, and found that the peptides bound to Grp78, as well as identified peptides 
homologous to TIMP-2 [198]. Hamzah, et al., used in vivo phage display to identify 
peptides binding to fibrin-fibronectin complexes in atherosclerotic lesions of ApoE-/- 
mice, and showed that a peptide know to target tumor macrophages was also useful for 
targeting atherosclerotic plaques [180]. These studies demonstrate the utility of phage 
display in discovering ligands that can be used to target nanomedicines to 
atherosclerosis. However, a major shortcoming of these studies is that they target 
mature lesions. An ideal strategy would target atheroprone regions of the vasculature 
before the development of advanced lesions. 
THESIS HYPOTHESIS AND SPECIFIC AIMS 
Disturbed flow is a key initiating event in atherosclerotic lesion formation. 
Atherosclerotic lesions develop when focal endothelial dysfunction caused by disturbed 
flow is compounded by systemic risk factors such as hypercholesterolemia. Targeted 
drug delivery to areas of disturbed flow is a promising approach to prevent 
atherosclerosis before lesions develop. Studies have shown that disturbed flow can 
develop at many cites, making prediction of these atheroprone areas speculative [199, 
200]. Therefore programming nanocarrier functions to navigate to and detect 
atheroprone areas is an ideal but unmet need. In this thesis, I sought to use phage 
display to identify biomarkers in endothelial cells exposed to disturbed or atheroprone 
flow. I hypothesized that peptides targeting atheroprone vascular zip codes could be 
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identified by phage display, and that these ligands could be leveraged for 
nanotheraputic targeting to atheroprone vasculature (figure 7).  
 
Figure 7. Nanocarrier targeting to atheroprone vasculature (red). 
Specific aim 1 – Identification of atheroprone vascular zip codes. In this aim, phage 
display was utilized to discover novel peptide ligands that selectively target endothelial 
cells in atheroprone vasculature. 
Specific aim 2 – Nanotherapeutic platform development. In this aim we employed phage 
displayed peptides to create targeted nanoparticles, and evaluated nanoparticle homing 
to atheroprone vasculature in vivo.  
Specific aim 3 – Therapeutic delivery. In this aim targeted nanoparticles were used to 
deliver tetrahydrobiopterin to rescue endothelial dysfunction and prevent 
atherosclerosis.  
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CHAPTER II 
 
IDENTIFICATION OF ATHEROPRONE VASCULAR ZIP CODES USING PHAGE 
DISPLAY 
 
INTRODUCTION 
Arterial geometry affects the blood flow profiles in the cardiovascular system. In straight, 
unbranched vascular segments blood flow is unidirectional and laminar. The time 
average wall shear stress is high. In contrast, at branch points, sites of curvature and 
distal to stenosis, blood flow becomes disturbed. Endothelial cells comprise the inner 
lining of blood vessels and experiencing these changes respond with distinct alterations 
in phenotype. Disturbed flow predisposes these regions to local lipid deposition, 
inflammation and focal development of atherosclerosis. Atherosclerotic lesions 
predominantly occur at these sites: branch points, the proximal coronary arteries and 
the distal aorta [48, 125, 126]. Current therapies for atherosclerosis do not employ 
preventative treatments to target vasculature that is prone to develop the disease. 
Therefore, there is an unmet need to define ligands that can target therapeutics to 
regions of disturbed flow. 
Given the marked differences in gene expression and protein content of endothelial 
cells exposed to varying flow profiles, we reasoned that there might be differences in 
peptide binding to the surface of cells exposed to disturbed versus unidirectional 
laminar shear. This is supported by recent evidence demonstrating that endothelial cells 
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present a heterogeneous luminal protein milieu specific to their tissue of origin [191, 
192, 201, 202]. This diversity of protein expression on the luminal surface of the 
vasculature is currently being leveraged for the discovery of tissue and disease specific 
ligands for drug targeting [174, 180, 181, 203]. Phage display employing combinatorial 
peptide libraries is widely accepted to screen peptide motifs that bind specifically to 
vascular beds of interest [177, 178, 181, 193, 194, 204-206]. In the context of vascular 
disease, phage display has facilitated development of affinity agents targeted to mature 
atherosclerotic lesions [178-180, 207].  
APPROACH 
In this aim I employed phage display in vitro and in vivo to identify peptide ligands that 
bind to endothelial cells exposed to disturbed flow. Consensus peptide sequences 
targeting atheroprone flow were then validated in vivo. To further validate peptide 
targeting, fluorescently labeled peptides were synthesized and injected in the same 
murine model system and flow cytometry was performed to identify cell types that 
preferentially take up peptides in the atheroprone artery.  
METHODS 
Cone-in-plate culture system 
We first attempted to identify targeting ligands to oscillatory shear stress by using phage 
display in vitro in a cone-in-plate culture system. Cone-in-plate cell culture, pioneered by 
C. Forbes Dewey, has become a well-established method to subject living cells to fluid 
shear stress [70, 71]. A schematic representation of the cone-in-plate system with 
calculations for shear stress at the cell surface is shown in Figure 1A. I developed an 
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improved cone-in-plate culture system based on the Forbes Dewey design (Figure 1B). 
We employed 9 cm titanium cones, with a one-degree cone angle in this system. The 
cones were coupled to stepper motors by ½ inch stainless steel shafts using a flexible 
shaft coupler. The shaft coupler serves to minimize misalignment of the motor with the 
cone system and reduce wobble caused by a misaligned system. Ten-centimeter 
culture plates were stabilized in a polymer base with four plate holders. The cones were 
held in place by type 2 polyvinyl chloride plate covers, which were fastened in place 
using brass nuts. The plate covers also set the offset height of the cones by holding the 
shaft in place using a stainless steel shaft collar. The offset height for all cone-in-plate 
experiments was set to 0.012 inches. Motors were held in place by a ¼ inch G-10 
fiberglass platform with motor mounts designed for NEMA 17 stepper motors. Motor 
drivers adapted from an older cone-in-plate culture system were used to power motors.  
 
Figure 1. Cone in plate culture system A) Schematic of the cone-in-plate culture system 
and method for calculating fluid shear stress based on a no-slip condition at the cell 
surface and Newtonian fluid mechanics using Poiseuille’s law B) Cone-in-plate culture 
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system developed for in vitro phage panning. The culture plate is placed underneath the 
grey type two PVC holder. 
Cell culture 
Human aortic endothelial cells (hAECs) were purchased from Lonza and cultured 
according to manufacturers protocols using Endothelial growth medium 2 with a full 
bullet kit supplement and 3% serum (Lonza, Basel, Switzerland). 
In vitro phage display 
In vitro panning was performed using subtractive panning against hAECs exposed to 
laminar (+13 dPa) vs. oscillatory shear (±13 dPa) in a cone-in-plate culture system. 
Endothelial cells were cultured to confluence and subjected to shear stress for 15 hours 
24 hours after confluence was reached. Two M13 bacteriophage peptide libraries, a 7 
amino acid cyclic library, and 12 amino acid linear library (New England Biolabs, 
Ipswich, MA, Cat# E8110S, and E8120S, respectively), were used in screening. Two 
libraries (i.e., cyclic and linear) were used because structural specificity can impact 
peptide binding affinity, and the cyclic peptide library displays a common motif in ligand 
binding. Subtractive panning increases panning stringency and therefore binding 
specificity of the phage. Subtractive panning involves first incubating the phage library 
with hAECs exposed to laminar shear and then transferring the supernatant containing 
un-bound phages to incubate with hAECs exposed to oscillatory shear. A first round of 
panning was performed against only oscillatory shear exposed hAECs while round 2-4 
employed the subtractive panning technique. For all panning rounds hAECs were 
washed 10 times with tris buffered saline (TBS) containing 0.1% Tween 20 (TBST) after 
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phage incubation, and then phages were eluted by non-specific elution buffer containing 
0.2 M glycine-HCl and 1mg.mL-1 BSA with a pH of 2.2.  
The eluted phages were then used to transform Escherichia coli (E-coli) for amplification 
and to quantify the number of phage binding to the target condition by titration. 
Visualizing β-galactosidase (β-gal) positive plaques allowed quantification of phage titer. 
Phage eluted from oscillatory shear hAEC were expanded and then used for the next 
round of panning (Figure 2).  
 
Figure 2. Schematic of in vitro phage panning process. A) Schematic of cone-in-plate 
viscometer cell culture. B) Schematic of subtractive panning, where phage are first 
introduced to laminar sheared cells then exposed to oscillatory sheared cells. C) 
Isolation of phage clones after phage panning for titration, sequencing and recycling for 
the next round of phage display. 
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Lysogeny broth (LB)-agar plates for titration contained 0.2 mM isopropyl-β-D-
thiogalactoside, 0.1 mM 5-Bromo-4-chloro-3-indolyl-β-D-galactoside, 10g.L-1 Bacto-
Tryptone, 5 g.L-1 yeast extract, 10 g.L-1 NaCl, and 15 g.L-1 agar. Visualizing β-gal 
positive colonies allowed for quantification of phage titer. After the third and fourth round 
of phage panning, ten colonies were sequenced from titration plates to identify 
consensus sequences. For sequencing, colonies were picked using sterile pipet tips 
and deposited into 30 µL Platinum® PCR Supermix (Invitrogen, Grand Island, NY, Cat# 
11306-016) containing 0.5 µM forward and reverse primers (Forward primer 5’-
GTCATTGTCGGCGCAACTATCGG-3’, Reverse primer 5’-CCC TCA TAG TTA GCG 
TAA CG-3’). Amplified DNA fragments were purified using QIAquick PCR spin columns 
(Qiagen, Hilden, Germany, Cat# 28104), and diluted in DNAse free water for 
sequencing. Sanger sequencing was performed at the Vanderbilt Technologies for 
Advanced Genomics using the reverse primer from PCR amplification [208]. 
Animals studied  
Wild-type C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). 
The institutional animal care and use committee at Vanderbilt University approved all 
animal protocols. All in vivo experiments were performed in a partial carotid artery 
ligation model of disturbed flow [74]. Male mice at age of 10 to 14 weeks underwent a 
surgical procedure in which the left common carotid artery (LCA) was exposed and 
three of four of its branches: the left external carotid artery (ECA), left internal carotid 
artery (ICA), and the occipital artery (OA) were ligated with 6-0 silk suture while the 
superior thyroid artery (STA) was left intact (Figure 3). Care was taken to avoid 
damaging the superior thyroid artery during ligation. The right common carotid artery 
(RCA) was surgically exposed, but not ligated, and served as a sham control. Doppler 
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ultrasound was performed using a VisualSonics Vevo 770 (Fujifilm VisualSonics, Inc., 
Toronto, Canada) micro imaging system to visualize blood flow in the ligated and un-
ligated arteries. Images were acquired using the RMV-704 ultrasound probe 
transmitting at 100% power at a frequency of 30 MHz with a receiving Doppler gain of 
10 dB. 
 
Figure 3. Schematic of the partial carotid artery ligation surgery. Three of the four 
ascending branches of the left carotid artery are ligated, resulting in partial occlusion of 
the left carotid artery and disturbed shear in the left common carotid artery. 
In vivo phage display 
In vivo phage display was performed in C57/BL6 mice four days post-ligation. Two 
peptide libraries were used screened in this study, the Ph.D.-12 and Ph.D.-C7C 
libraries. Phage peptide libraries were injected into the tail vein of the mice at a 
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concentration of 2 x 1011 plaque forming units to ensure a 100 fold representation of all 
clones in the phage library containing a theoretical 2 x 109 different clones. After 2.5 
hours of circulation time, mice were euthanized by CO2 asphyxiation, perfused at 
physiological pressure with normal saline containing 10 U.mL-1 heparin, and then both 
carotid arteries were surgically removed and processed separately. In order to remove 
un-bound phages, the excised arteries were cannulated with a 30-gauge syringe and 
washed with 0.5 mL TBST then transferred to fresh TBST. To expose the endothelium, 
each artery was cut lengthwise with a number 10 scalpel. Arteries were then washed 
with non-specific elution buffer consisting of 0.1 M glycine-HCl (pH 2.2) with 1 mg.mL-1 
bovine serum albumin to remove phages bound to the surface of the vessels, and 
weakly bound phages. Next, phages were eluted with 100 mM triethanolamie in TBS 
[178]. The eluted phages were then used to transform E. coli for amplification, and the 
number of phages binding to the target condition was quantified by titration according to 
the manufacturer’s protocol. For amplification, E. coli were transformed at early-log 
phase (OD600 = 0.01-0.06) with phages and cultured for 4.5 hours with vigorous 
shaking. Phages were then purified by ultracentrifugation and overnight precipitation 
into 20% w/v polyethylene glycol (M.W. = 8000) with 2.5 M NaCl. Amplified phages from 
the LCA were then used in the subsequent rounds of phage display following the same 
procedures. 
To validate the affinity of consensus sequences, consensus clones were amplified as 
described previously by inoculating an E. coli culture with a consensus clone colony, 
and injected following the same procedures as in vivo phage library panning. Titration of 
phages binding to the LCA vs. RCA was used to determine the relative affinity for the 
target condition. The titer of phages recovered was normalized to the protein content of 
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the corresponding vessel. For measurement of protein concentration carotid artery 
segments were placed in 50 µL of RIPA lysis buffer (Thermo Scientific, Rockford, IL, 
Cat# 89900) containing protease and phosphatase inhibitors (Roche, Indianapolis, IN, 
Cat# 05892970001, and Cat# 04906845001, respectively); and sonicated for one 
minute on ice to release protein. Protein content was measured by small volume BCA 
assay (Thermo Scientific, Cat# 23225). 
Peptide synthesis 
Peptides were synthesized on a PS3 3 channel serial peptide synthesizer (Protein 
Technologies, Inc. Tucson, AZ) on low substitution glycine loaded Wang or 2-chlorotrityl 
resin support using standard solid phase Fluorenylmethyloxycarbonyl chloride (Fmoc) 
chemistry. N-methylpyrrolidone (NMP, Fischer Scientific) was utilized as a solvent in all 
peptide syntheses. O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate was used as an activator (Chempep, Wellington, FL) in the 
presence of N-methylmorpholine. All amino acids were double coupled in order to 
maximize yield and purity. Peptides were cleaved and de-protected in trifluoroacetic 
acid/water/triisopropylsilane (95/2.5/2.5). Successful peptide synthesis was verified 
through electrospray ionization mass spectrometry (ESI-MS) analysis on a Waters 
Synapt ESI-MS. The peptide was then further purified by reverse phase high 
performance liquid chromatography (HPLC) on a Waters 1525 binary HPLC pump 
outfitted with an extended flow kit, a Waters 2489 UV/Visible detector and a 
Phenomenex Luna C18(2) AXIA packed column (100A, 250 x 21.2  mm, 5 micron). 
HPLC grade water with 0.05% formic acid (solvent A) and HPLC grade methanol with 
0.05% formic acid (Solvent B) were used as the mobile phases and the peptide was 
purified utilizing a 90% A to 90% B gradient over 25 minutes at a flow rate of 16 mL.min-
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1. Methanol was removed from purified fractions with a rotary evaporator and the 
purified fractions were then frozen and lyophilized. Peptide purity was verified through 
ESI-MS. 
Evaluating peptide uptake in vivo by flow cytometry  
To further validate the efficacy of peptide targeting, peptides were injected 
intravenously, and cellular uptake was determined by flow cytometry. SLSSYNGSALAS 
(DistL12) and GSPREYTSYMPH (PREY) peptides were fluorescently labeled at the N-
terminus by reaction with 5(6)-Carboxyfluorescein (FAM) N-Hydroxysuccinimide ester 
(NHS). Peptides were dissolved in 0.1 M bicarbonate buffer (pH = 8.3) and reacted 
overnight on ice with 4 molar eqivalents of NHS-FAM. The resultant FAM-Peptides were 
purified by gel filtration through Spehadex columns (PD MidiTrap G10, GE Healthcare). 
Purified FAM-Peptide solutions were frozen and lyophilized to a dry powder.  
For flow cytometry experiments, mice underwent partial carotid ligation surgery 4 days 
before peptide injection. The mice were injected with 4mg.kg-1 FAM-peptide 2.5 hours 
before sacrifice. The mice were then perfused through the left ventricle with ice cold 
PBS with calcium and magnesium, and arteries were collected and stored on ice. To 
obtain cell suspensions for single stain and fluorescence minus one (FMO) control 
experiments the aorta from one FAM-peptide injected mouse and one control mouse 
were also isolated and cleaned of perivascular fat and lymph nodes prior to processing. 
For peptide injection samples, two mice were pooled per sample to ensure that enough 
cells were collected for analysis. To obtain single cell suspension solutions from sample 
arteries, the arteries were placed into a digestion solution consisting of phenol red free 
RPMI 1640 medium (Gibco) with glutamine, 10% fetal bovine serum, 1 mg.ml-1 
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collagenase A, 1 mg.ml-1 collagenase B, and 0.1 mg.ml-1 DNAse 1 (Roche). The 
arteries were minced with sharp scissors for two minutes and then placed on a shaker 
for 30 minutes at 37 ˚C. Next, the arteries were passed through a 70 µm cell strainer to 
obtain cell suspensions. The cell strainer was washed three times with 10 mL RPMI to 
recover dissociated cells. Next the cells were spun at 300 xg for 10 minutes and then 
transferred to fluorescence-assisted cell sorting (FACS) tubes for further processing. All 
future steps took place in FACS buffer consisting of phosphate buffered saline (PBS) 
with calcium and magnesium, 1% bovine serum albumin and 0.1% sodium azide. Next, 
non-specific antibody binding was blocked with anti-CD16/CD32 for 10 min at 4 °C 
(BDbiosciences, clone 2.4G2, Cat# 553142) (2 µL in 100uL FACS buffer). The cells 
were then subjected to a low-speed centrifugation at 300 x g for 5 minutes and washed 
once with 1 mL of FACS buffer. Staining solutions were made by adding 1 µL of each 
antibody solution to 100 µL FACS buffer. Cells were incubated with staining solutions 
for 30 minutes at 4 ˚C and then washed twice with FACS buffer. For live/dead staining, 
the cells were then incubated with 7-aminoactinomycin-D (7-AAD) for 10 minutes at 
room temperature before running on the flow cytometer. Fluorescein isothiocyanate 
(FITC) beads were used for single stain and compensation controls to set the detection 
parameters for the flow cytometer.  
Single stain and FMO samples were used to set up gating for positive events. Platelet 
endothelial cell adhesion molecule (CD31) was used as a marker for endothelial cells, 
protein tyrosine phosphatase receptor type C (CD45) as a marker for all leukocytes, and 
epithelial growth factor-like module-containing mucin-like horomone receptor-like 1 
(F4/80) as a marker for monocyte/macrophages. Dead cells were eliminated using 7-
AAD. Antibody information can be found in Table 1. For analysis, I first gated for live 
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cells (negative for 7-AAD) and then for single cells based on forward scatter area vs. 
forward scatter height. Next, I plotted cells positive for CD31 vs. cells positive for CD45 
to investigate cell population specific uptake.  
 
Determining a potential binding partner for the PREY peptide 
To determine the binding partner for the PREY peptide, I performed a pull-down 
followed by proteomics analysis. For proteomics experiments, all peptides were N-
acetylated by reaction with acetic anhydride. PREY peptides, and scrambled PREY 
control peptides were conjugated at the C-terminus with 5-(Biotinamido)pentylamine 
(pentylamine-biotin) by 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)- N-
hydroxysulfosuccinimide (sulfoNHS) coupling (EZ-Link Pentylamine-Biotin, Fisher 
Scientific, Rockford, IL). Conjugates were purified by dialysis overnight to remove 
excess pentylamine-biotin. Conjugation products were confirmed by esi-MS. Two 
milligrams of each peptide-biotin conjugate was mixed with 1 milligram streptavidin 
conjugated paramagnetic particles (Magnesphere, Promega, Madison, WI). To remove 
excess peptide, beads were washed 5 times prior to use. For pulldown experiments, 
mice were sacrificed 4 days after partial carotid ligation surgery. Carotid arteries were 
Table 1. Flow cytometry antibody information. 
Antibody Fluorophore Target Company/cat# Clone 
αCD31 PE Endothelial 
cells 
BD pharmingen/ 
561073 
MEC 13.3 
αCD45 Brilliant violet 
510 
Leukocytes BioLegend/ 
103137 
30-F11 
αF4/80 APC/Cy7 Macrophages BioLegend/ 
123118 
BM8 
7AAD PerCP-Cy5.5a Dead cells BS Pharmigen 
51-68981E 
NA 
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removed, immediately frozen in liquid nitrogen and homogenized on dry ice. Artery 
homogentate was dissolved in 800 µL NP40 buffer (0.5% triton-100 in tris buffered 
saline pH=7.8 with protease inhibitors), and insoluble proteins were cleared by 
centrifugation. Four hundred µL of protein was mixed with 100 µg peptide conjugated 
beads and incubated for 1.5 hours at room temperature. Beads were washed 4 times 
with NP40 buffer, and proteins were eluted with 30 µL of 1x activated Laemmli buffer by 
heating to 70 °C for ten minutes. 
Shotgun proteomic analysis of eluate was performed by first resolving eluted proteins 
approximately 1 cm using a 10% Novex precast gel, and then performing in-gel tryptic 
digestion to recover peptides. 
Resulting peptides were analyzed by a 70-minute data dependent LC-MS/MS analysis. 
Briefly, peptides were autosampled onto a 200 mm by 0.1 mm (Jupiter 3 micron, 300A) 
self-packed analytical column coupled directly to an LTQ (ThermoFisher) using a 
nanoelectrospray source and resolved using an aqueous to organic gradient.  A series 
of a full scan mass spectrum followed by 5 data-dependent tandem mass spectra 
(MS/MS) was collected throughout the run and dynamic exclusion was enabled to 
minimize acquisition of redundant spectra.  MS/MS spectra were searched via 
SEQUEST against a mouse database that also contained reversed version for each of 
the entries. (http://www.ncbi.nlm.nih.gov/pubmed/7741214).  Identifications were filtered 
and collated into spectral count numbers at the protein level using Scaffold (Proteome 
Software). 
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Immunoblotting 
The presence of Fibronectin and Filamin-A in the pulldown was confirmed by western 
blot. Pulldowns were performed as described previously and eluted protein was used for 
western blot. Proteins separated by 4-20% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), and transferred to polyvinylidene fluoride (PVDF) 
membranes overnight at 30 V at 4 °C. Membranes were blocked for 1 hour in 5% milk in 
0.1% TBST. Anti-Filamin-A antibody (ab51217, Abcam, Cambridge, MA), and anti-
fibronectin antibody (ab23750, Abcam) were diluted 1:500 in TBST and incubated with 
the membranes for 1 hour at room temperature. Filamin-A was visualized as a single 
band at 281 kDa in western blots. Fibronectin was visualized as a single band at 265 
kDa. Because the protein used for western blot was from pulldown, a loading control 
was not possible. However, the amount of protein loaded onto the peptide-
functionalized beads was equivalent, as was the substitution of the peptide on the 
beads. This indicates that the differences in band intensity from pulldown experiments is 
due to differences in expression in the vessels, not unequal loading. 
Immunostaining  
Immunofluorescence staining was performed on fix-perfused mouse carotid arteries 
embedded in optimum cutting temperature medium (OCT, Tissue-Tek). Five micron 
sections were sliced in a serial sequence. Samples were permeablized with 0.1% Triton 
X-100 (Sigma-Aldrich). Antigen blocking was performed with 5% bovine serum albumin 
(BSA) prior to incubation with anti Filamin-A antibody (ab51217, Abcam). Additional 
blocking with 10% donkey serum was performed before incubation with secondary 
antibodies. Donkey polyclonal antibodies conjugated to Alexa Fluor 488, 555 or 647 
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were used for binding primary antibodies. Where applicable, samples where then 
subsequently incubated with phallodin-Alexa-488 (Life Technologies) for visualization of 
F-actin. 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen) was added in the last wash 
following incubation with secondary antibodies or phalloidin. All slides were mounted 
with Prolong Anti-fade media (Life Technologies). 
RESULTS AND DISCUSSION 
Cone-in-plate culture 
According to calculations performed according to figure 1A, the shear stress 
experienced by the cells varies from the center of the dish to the outside, but most cells 
experience physiological shear stress around 13 dPa (Figure 4A). In our system, hAEC 
were shown to align and elongate under laminar shear, whereas the unaligned, irregular 
cobblestone morphology was seen when exposed to oscillatory shear stress (Figure 
4B). The observed cellular morphology in our culture system is the same as previously 
observed and validated the physiological response of endothelial cells to differential 
shear waveforms [209].  
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Figure 4. hAEC culture in the cone-in-plate system A) Calculation of shear stress as a 
function of distance from the center of the plate according to equations from figure 1A. 
B) Examples of hAEC cultured with oscillatory shear (top) and laminar shear (bottom). 
Red = F-actin, Blue = nucleus. 
In vitro phage panning 
Eluate titers from the fourth round of in vitro panning indicated an increase in specificity 
for hAEC exposed to oscillatory shear stress of 1.9 fold (p>0.05, n=2) for linear libraries 
and 1.37 fold (p=0.03, n=2) for cyclic libraries. However, no consensus sequence was 
identified from in vitro panning (Figure 5). This result was indicative of successful 
biopanning, which increased specificity for the target condition but did not result in a 
consensus. Additionally, the displayed peptides do not contain an abundance of 
aromatic residues. Aromatic residues have been shown to mediate nonspecific phage 
binding to polystyrene and other plastics [210]. Therefore, a lack of aromatic residues 
indicated that the phage bound to cellular targets and not to culture dishes used for 
these experiments. These results indicated the feasibility of the phage display approach 
for discovering peptides that preferentially bind to endothelial cells exposed to disturbed 
flow. It is also notable that the flow pattern achieved in a cone-in-plate culture device 
are not as complex as observed in vivo because it is improbable to create turbulent flow 
at the length scale of a cone-in-plate culture using more closely Newtonian fluids. While 
endothelial cells phenotype is similar to the in vivo case in terms of gene and protein 
expression, there is a possibility that the display of proteins on the cell surface in a 
cone-in-plate culture differs from the display of proteins on the luminal surface of 
vasculature. This system also lacks the dynamic interaction with circulating blood cells 
such as platelets, erythrocytes, monocytes and T lymphocytes, which could alter 
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endothelial phenotype. I decided to pursue in vivo phage panning due to these 
limitations of in vitro culture, and the fact that no consensus clones were identified from 
in vitro panning. 
 
 
 
Figure 5. Titration of phage recovered from in vitro phage panning. The number of 
phage recovered from subtractive panning indicated that the in vitro phage panning 
process was selecting phage clones that accumulated in the oscillatory shear condition. 
In vivo phage panning 
In vivo phage panning was performed in the partial carotid artery ligation model of disturbed flow 
in male C57/BL6J mice [74, 211]. In this surgical model, three of the four major branches of the 
left common carotid artery (LCA) are ligated. This results in low and oscillatory flow in the LCA, 
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while flow in the right common carotid artery (RCA) remains normal. Doppler ultrasound imaging 
confirmed disturbed blood flow in the ligated LCA and normal blood flow in the sham RCA one 
day after ligation (Figure 6). The ligated left carotid artery is the target for phage display, while 
the right artery serves as a normal flow control. 
 
Figure 6. Ultrasound performed 1 day post-ligation demonstrating low velocity 
atheroprone flow and flow reversal in the ligated LCA (top) and normal pulsatile and 
unidirectional flow in the unligated RCA (bottom). 
Four days post-ligation in vivo phage display was performed. Phages were injected into 
the tail vein of the mice at a concentration of 2 x 1011 plaque forming units. After 2.5 
hours mice were sacrificed by CO2 inhalation, and the carotid arteries were surgically 
isolated, and phages were recovered from the vessels. To increase stringency of the 
screening process and specificity of the phages for the target condition, arteries were 
washed with acidic buffer to remove weakly bound phages, and the remaining phages 
were recovered by cell lysis and amplified in bacteria. These phages were then re-
injected in other mice with partial carotid ligation. This strategy of using successive 
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rounds of injection, isolation by cell lysis and re-amplification has been used previously 
to isolate phages that are internalized by target cells [178]. Selecting ligands that could 
mediate nanoparticle internalization into target cells is desired when cytoplasmic 
delivery of a drug is necessary, and helps to increase signal for imaging applications. 
After each round of phage display, titration of the phage recovered from the arteries was 
used to quantify relative uptake in the target LCA and control RCA. After each round, 
phage isolated from the target LCA were amplified, purified and re-injected for the 
subsequent round of phage display. 
Figure 7 shows examples of phage isolations following each round of injections. From 
round one to round four there was a progressive increase in the number of phages 
binding to the target LCA (top) and no increase in binding to the RCA (bottom). The 
increased binding to the target LCA indicated that clones were being selected that 
preferentially accumulated in vessels exposed to disturbed flow.  
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Figure 7. In vivo phage display titration results. The top plates are infected with M13 
recovered from the ligated LCA and have progressively more plaques (black dots) in 
each round while the lower plates are infected with M13 from the RCA and do not 
increase in number with each progressive round of phage display. 
After round three and four of phage screening, 10 plaques from titration plates were 
sequenced. Four peptide sequences were identified as dominating those that selectively 
accumulated in the regions of disturbed flow. Two of these encoded linear 12 amino 
acid peptides, SLSSYNGSALAS, and, GSPREYTSYMPH. Two sequences that 
encoded 7 amino acid cyclic peptides were also identified, ACNTGSPYEC, and, 
ACTPSFSKIC. Protein BLAST was used to identify potential protein interactions (Table 
2). 
Table 2. Protein homology of phage displayed consensus peptides. 
Sequence Name Identity sequence Accession # 
SPREYTSYMPH Myoferlin 496-SPREYT-501 NP_001093104 
SLSSYNGSALAS 
Eyes absent homolog 
1 isoform 2 
27-SLDSFSGSALGS-38 NP_001239121 
ACNTGSPYEC Zinc finger protein 160-CHTGEKPYEC-169 AAA64428 
ACTPSFSKIC 
Calsyntenin 1, 
isoform CRA_b 
187-CSPQFSQIC-195 EDL14871 
 
Next I sought to verify that the consensus clones selectively target the atheroprone left 
carotid artery. In additional experiments, I amplified and injected these consensus 
clones following the same procedures as in vivo phage library panning. Titration of 
phage normalized to the protein content of the corresponding LCA or RCA was used to 
determine the relative uptake between the target and control arteries. All four 
consensus clones showed a significantly increased binding to the targeted LCA. 
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ACTPSFSKIC showed average enrichment of 7.3 fold, SLSSYNGSALAS showed 
enrichment of 4.9, and ACNTGSPYEC showed enrichment of 6.1, and 
GSPREYTSYMPH showed enrichment of 4.4 in the target artery (Figure 8). In addition, 
when these phages were injected into mice that had undergone a sham surgery 4 days 
previously, they did not accumulate differently between the LCA and RCA, which 
indicates that the consensus clones do not target the LCA in the absence of disturbed 
flow.  These experiments confirmed that the consensus peptides discovered in the initial 
screen specifically accumulate in regions of disturbed flow.  
 
Figure 8. Clone injection titration demonstrates that all phage clones result in 
significantly greater binding to the ligated LCA. *, p < 0.05 between the RCA and LCA. 
Next I sought to determine if the consensus peptide sequences targeted atheroprone 
vasculature in the absence of the phage particle. Two of the phage clones, 
SLSSYNGSALAS (DistL12) and GSPREYTSYMPH  (PREY) were synthesized and 
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fluorescently labeled in order to measure their uptake in target tissue by flow cytometry. 
Flow cytometry of ligated arteries demonstrated increased immune cell infiltration into 
the ligated LCA compared to the unligated RCA, likely due to inflammatory activation of 
the endothelium as a result of disturbed flow. When individual populations of cells were 
examined for peptide uptake, the peptide PREY showed significantly greater binding to 
the atheroprone LCA compared to the un-ligated RCA. In addition, accumulation was 
seen in both endothelial and leukocytes but not in macrophages or other cells. This 
indicates that the uptake mechanism is likely due to a specific interaction and not a 
result of nonspecific uptake by macrophages. When injected intravenously, the 
fluorescently labeled peptides are cleared from the body very quickly. I hypothesize that 
rapid renal clearance resulted in minimal uptake in the targeted tissue. I decided to 
pursue this line of inquiry further with peptide-functionalized nanoparticles, which should 
have significantly longer circulation time. 
 
Figure 9. Flow cytometry results after FAM-labeled peptide injections demonstrated 
increased PREY uptake in the left carotid artery in endothelial cells and leukocytes.  
The phage displayed peptide GSPREYTSYMPH (PREY) was chosen for further study 
due to its homology to murine myoferlin and low level of background binding to right 
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carotid artery. Myoferlin has regulatory roles in endothelial cells as it is critical for 
endocytosis, regulates vascular endothelial growth factor receptor-2 (VEGFR2) stability 
and function, and is implicated in endothelial membrane repair [212-214]. This peptide 
is an interesting candidate because VEGFR2 is known to play a role in 
mecahnotransduction, and endothelial membrane damage has been observed in 
disturbed shear stress. In addition, myoferlin is enriched in caveolae, which are also 
implicated in endothelial cell response to shear stress [215, 216]. I reasoned that the 
PREY peptide might bind to Caveolin-1, which is upregulated under oscillatory shear, 
and performed additional experiments to test this hypothesis.  
To determine the binding partner for the PREY peptide, I employed a pull-down followed 
by proteomics analysis. The phage displayed peptide Acetyl-GSPREYTSYMPHGSGS-
COOH (PREY) and the scrambled control peptide Acetyl-THRPMSSYEPGYGSGS-
COOH (scrambled PREY) were synthesized by solid phase peptide synthesis. PREY 
peptides, and scrambled PREY control peptides were conjugated at the C-terminus with 
pentylamine-biotin by EDC-sulfoNHS coupling Biotinylated peptides were used to 
functionalize streptavidin conjugated paramagnetic particles. For pull-down 
experiments, mice were sacrificed 4 days after partial carotid ligation surgery. Carotid 
arteries were removed, immediately frozen in liquid nitrogen and homogenized on dry 
ice. Artery homogenate was dissolved in NP40 buffer and insoluble proteins were 
separated by centrifugation. Artery protein was incubated with peptide-conjugated 
beads for 1.5 hours. The beads were then washed and bound proteins were eluted in 
activated Laemmli sample buffer for further analysis. 
Proteomic analysis indicated that several proteins from the vessels with disturbed flow 
bound to PREY but not by scrambled PREY controls (Table 3). The top candidates 
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identified by proteomic analysis could form a complex and be involved in 
mechanosensing [217]. I first investigated PREY binding to fibronectin, which is known 
to play critical roles in endothelial mecahnotransduction and activation. Recent reports 
have shown that oscillatory shear stress increases fibronectin in the extracellular matrix 
in vivo [218, 219]. I also investigated Filamin-A, an actin binding protein involved in 
cytoskeletal remodeling, regulation of cell migration and cell shape, and anchoring 
glycoproteins at the cell surface [220]. Filamin-A interacts with caveolin and myoferlin, 
and was chosen for further study due to the homology of the PREY peptide to murine 
myoferlin [221, 222]. In addition, a recent report shows that Filamin-A may be displayed 
on the cell surface in malignant cells [223]. Microarray studies have shown that Filamin 
mRNA is increased twofold in murine endothelial cells exposed to oscillatory shear 
compared to laminar shear [224]. Filamin is also recruited to sites where stress is 
applied to integrins [225, 226].  
Table 3. Proteins identified by proteomics analysis. 
Identified Proteins Accession Number Molecular 
Weight 
Scrambled 
Abundance 
Targeted 
Abundance 
Myosin-11 tr|E9QPE7|E9QPE7 223 kDa 0 53 
Filamin-A sp|Q8BTM8|FLNA 281 kDa 0 35 
Vimentin sp|P20152|VIME 54 kDa 0 25 
Protein Col6a3 tr|E9PWQ3|E9PWQ3 354 kDa 0 24 
Fibronectin sp|P11276|FINC 265 kDa 0 17 
Actin, aortic smooth 
muscle 
sp|P62737|ACTA 42 kDa 1 16 
Serum albumin sp|P07724|ALBU 69 kDa 1 15 
Basement 
membrane-specific 
heparan sulfate 
proteoglycan core 
protein 
tr|B1B0C7|B1B0C7 469 kDa 0 12 
Collagen alpha-1(I) 
chain 
sp|P11087|CO1A1 138 kDa 1 8 
Tubulin beta-4B 
chain  
sp|P68372|TBB4B 50 kDa 0 7 
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Collagen alpha-
2(VI) chain  
sp|Q02788|CO6A2 110 kDa 0 6 
Collagen alpha-2(I) 
chain  
sp|Q01149|CO1A2 130 kDa 1 6 
Periostin  sp|Q62009|POSTN 93 kDa 0 6 
Fibrinogen beta 
chain  
sp|Q8K0E8|FIBB 55 kDa 0 6 
Alpha-actinin-1  sp|Q7TPR4|ACTN1 103 kDa 0 6 
Actin, cytoplasmic 1  sp|P60710|ACTB 42 kDa 0 5 
Prelamin-A/C  sp|P48678|LMNA 74 kDa 0 5 
Biglycan  sp|P28653|PGS1 42 kDa 0 5 
Tubulin alpha-1B 
chain  
sp|P05213|TBA1B 50 kDa 0 5 
Fibrinogen gamma 
chain  
sp|Q8VCM7|FIBG 49 kDa 0 4 
Decorin  sp|P28654|PGS2 40 kDa 0 4 
Fibrillin-1  sp|Q61554|FBN1 312 kDa 0 4 
Aconitate 
hydratase, 
mitochondrial  
sp|Q99KI0|ACON 85 kDa 0 4 
Protein Fga  tr|E9PV24|E9PV24 87 kDa 0 4 
Fatty acid synthase sp|P19096|FAS 272 kDa 0 4 
Collagen alpha-
1(VI) chain  
sp|Q04857|CO6A1 108 kDa 0 3 
Trifunctional 
enzyme subunit 
alpha, 
mitochondrial  
sp|Q8BMS1|ECHA 83 kDa 0 3 
Heat shock protein 
HSP 90-beta  
sp|P11499|HS90B 83 kDa 0 3 
Fibulin-5  sp|Q9WVH9|FBLN5 50 kDa 0 3 
Lumican  sp|P51885|LUM 38 kDa 0 2 
3-ketoacyl-CoA 
thiolase, 
mitochondrial  
sp|Q8BWT1|THIM 42 kDa 0 2 
Complement C3  sp|P01027|CO3 186 kDa 0 2 
Fatty acid-binding 
protein, adipocyte  
sp|P04117|FABP4 15 kDa 0 2 
Spectrin alpha 
chain, non-
erythrocytic 1  
sp|P16546|SPTN1 285 kDa 0 2 
Protein-glutamine 
gamma-
glutamyltransferase 
2  
sp|P21981|TGM2 77 kDa 0 2 
Collagen alpha-
1(XVIII) chain  
sp|P39061|COIA1 182 kDa 0 2 
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Myosin-10  sp|Q61879|MYH10 229 kDa 0 2 
Asporin  sp|Q99MQ4|ASPN 43 kDa 0 2 
Microfibril-
associated 
glycoprotein 4  
sp|Q9D1H9|MFAP4 29 kDa 0 2 
Beta-globin  tr|A8DUK4|A8DUK4 16 kDa 0 2 
Laminin subunit 
beta-2  
sp|Q61292|LAMB2 197 kDa 0 2 
Dedicator of 
cytokinesis protein 
11  
r-sp|A2AF47|DOC11 238 kDa 0 2 
 
Increased binding of fibronectin and Filamin-A to PREY functionalized beads in vessels 
with disturbed flow was further confirmed by immunoblotting. Pulldowns were performed 
as described previously and eluted protein was used for western blot. Fibronectin was 
visualized as a single band at 265 kDa (Figure 10A) and Filamin-A was visualized as a 
single band at 281 kDa (Figure 10B). These results showed greatest band intensity in 
both fibronectin and Filamin-A from ligated LCA with targeted peptide, confirming that 
the PREY peptide pulls down fibronectin and Filamin-A. These results also demonstrate 
that fibronectin and Filamin are selectively pulled down in greater quantity from the 
ligated artery compared to the unligated control. Because the PREY peptide specifically 
isolated several proteins from artery homogenate, I can hypothesize that the co-
precipitation of these proteins is due to binding of the PREY peptide with any one of the 
proteins identified by proteomics analysis that are connected to one another. These 
data indicate that the PREY peptide may bind to a protein complex involved in 
mecahnotransduction of disturbed shear. 
In additional experiments, I employed immunofluorescence to visualize Filamin-A in 
carotid arteries. These confirmed that Filamin-A protein expression is increased in 
vessels exposed to disturbed flow, and that it appears to localize with the luminal 
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endothelial cell surface (Figure 10C). Luminal localization of the proteins involved in 
binding is important considering that intravascular delivery of therapeutics would require 
a potential target to be displayed on the luminal surface.  
 
Figure 10. Validation of proteomic analysis A) Immunoblot of fibronectin after pulldown 
with PREY and scrambled PREY. B) Immunoblot of Filamin-A after pulldown with PREY 
and scrambled PREY. C) Immunostaining of Filamin-A in mouse carotid artery sections. 
Red= Filamin-A, Green = F-Actin, Blue = nucleus. Scale bars are 50 µm. 
CONCLUSIONS 
In this aim, I sought to use phage display biopanning to discover new biomarkers to 
allow the detection of atheroprone vasculature exposed to oscillatory shear stress. In 
vitro phage display was employed in a cone-in-plate culture system, which was 
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designed and characterized to show endothelial responses to flow under constant 
laminar versus oscillatory shear stress. In vitro biopanning in this system did not yield 
consensus peptides that could be used for further experiments. However, in vitro 
panning did demonstrate an increased affinity for the phage library to the cone-in-plate 
generated condition of disturbed flow. The lack of a consensus sequence from in vitro 
phage panning could indicate that the panning procedure was not stringent enough, or 
that the presence of too many molecular targets confounded analysis of phage clones 
recovered. I next performed phage panning in vivo in a partial carotid ligation model of 
disturbed flow. I reasoned that in vivo panning would allow me to screen peptides 
against a more physiologically relevant environment, and would also increase the 
stringency of the screening process. After four rounds of in vivo phage display I 
identified two linear and two cyclic peptide consensus that dominated the phage 
displayed libraries. I confirmed that these clones targeted atheroprone vasculature 
when injected in vivo. This indicates that all four of these peptides may be useful for 
targeting atheroprone vasculature. The two linear peptides were synthesized and 
fluorescently labeled to determine if the peptides could target atheroprone vasculature 
in the absence of the phage particle. These experiments demonstrated increased 
uptake of the PREY peptide in endothelial cells of the ligated artery, and minimal uptake 
in other cell types. The DistL12 peptide did not show differential uptake between the left 
and right carotid arteries. 
The PREY peptide was chosen for further analysis due to its homology with murine 
myoferlin, relatively low background biding to the RCA in clone injection experiments, 
and differential binding in fluorescently labeled peptide injection experiments. I 
performed a pulldown followed by proteomic analysis to determine a potential binding 
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partner for the PREY peptide. The top candidates identified in proteomic experiments 
are all implicated in endothelial response to shear stress. In addition, each of these 
proteins is potentially involved in integrin mediated signaling, and transferring 
mechanical tension to the actin cytoskeleton. These experiments demonstrated that the 
PREY peptide pulls down fibronectin and Filamin-A. From these results I can 
hypothesize that the PREY peptide is binding to any one of these proteins, which are 
bound to other top candidates. It is possible that these proteins are involved in 
mechanosensing of disturbed flow. 
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CHAPTER III 
 
TARGETED NANOPARTICLE DEVELOPMENT AND IMPLEMENTATION 
 
INTRODUCTION 
Given the ability to selectively target atheroprone vasculature, nanomedicine offers a 
promising set of tools for diagnosing, treating, and preventing atherosclerosis [227]. I 
therefore sought to use the PREY peptide to deliver nanocarriers to atheroprone 
vasculature. In this aim, I tested two different nanocarrier formulations Poly(ethylene 
glycol)-b-poly(propylene sulfide) (PEG-PPS) encapsulated ultrasmall 
superparamagnetic iron oxide (USPIOs) nanoparticles, and liposomes. 
PEG-PPS encapsulated USPIOs were chosen as a well-characterized nanoparticle for 
imaging applications. Iron oxides are garnering increased acceptance for diagnostic 
imaging [228]. Biodistribution of iron oxides used as an intravenous contrast agent for 
magnetic resonance imaging (MRI) is widely studied. Site-specific targeting of 
systemically administered nanoparticles can be achieved through the synergistic effect 
of molecular targeting and the nanoparticle’s physical and chemical properties [229-
232]. USPIOs provide several advantages for this application. Iron oxides have been 
rigorously demonstrated as biocompatible and in clinical use since 1983 [233, 234]. For 
imaging, they provide T2 and T2* MRI contrast, which enables in vivo localization with 
high sensitivity (roughly 12 times more sensitive than T1 agents) and short image 
acquisition times [235]. There are many examples of iron oxides encapsulated in PEG-
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PPS polymers to provide water dispersiblity and extended circulation time [236-238]. In 
addition, polymer chemistry can be finely tuned for peptide targeting and therapeutic 
delivery. Dextran coated USPIOs are clinically approved MRI contrast agents and 
numerous studies have investigated their biodistribution and clearance from the body 
[233]. 
Liposomes have many advantages for vascular nanomedicine due to their well-
documented biocompatibility, ability to carry hydrophilic, hydrophobic, or amphiphilic 
drugs. Liposomes also provide facile chemistry for targeting and extending circulation 
time [154]. Several liposomal formulations are already clinically approved for the 
treatment of various diseases, most notably doxorubicin encapsulated in liposomes 
[173]. In the context of vascular disease various liposomal targeting techniques have 
been employed for imaging and drug delivery and are reviewed in [227, 239-242].  
APPROACH 
In this aim I sought to validate nanoparticle targeting to atheroprone vasculature by 
functionalization of nanoparticles with the novel targeting ligands identified in aim 1. 
PEG-PPS polymers were synthesized and characterized and then conjugated with the 
peptides discovered by phage display. These nanocarriers were then evaluated for their 
ability to target atheroprone vasculature in the mouse partial carotid artery ligation 
model by MRI imaging. Liposomal nanocarriers were also functionalized with peptides 
identified by phage display and their ability to target atheroprone vasculature in vivo was 
evaluated by confocal microscopy. In additional experiments, I used flow cytometry to 
determine the cell types targeted by peptide-functionalized liposomes.  
METHODS 
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USPIO nanoparticle synthesis 
Oleic acid stabilized USPIOs with mean diameters of 3, 10, and 22 nm were fabricated 
by thermal decomposition according to the protocol provided by Prof. Todd D. Giorgio. 
All magnetic nanoparticles utilized in this project were provided by Dr. Shann Yu from 
the Giorgio laboratory. To synthesize USPIOS, oleic acid was heated to 100 ˚C in octyl 
ether in a three-neck flask. Fe(CO)5 was then added and the mixture was refluxed for 4 
hours at 280 ˚C. The mixture was cooled to 80 ˚C, aerated overnight, and then refluxed 
again for 2 hours at 280 ˚C. Varying ratios of Fe(CO)5 to oleic acid were added to 
achieve different particle diameters. In this synthesis scheme, increasing the molar ratio 
of oleic acid to decreases USPIO size [236, 243]. The oleic acid USPIOs used in this 
study having diameters of 3,10, and 22 nm. 
Polymer synthesis 
Poly(propylene sulfide) (PPS) was synthesized by anionic ring opening polymerization. 
Under anhydrous conditions, 3 molar equivalents 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(DBU) was added to 1mole equivalent of ethanethiol initiator and the reaction was 
brought to 0 ˚C on ice. Propylene sulfide was added by syringe addition with the ratio of 
propylene sulfide monomer to initiator determining the molecular weight. In this case, 
11.2 mL DBU was mixed with 1.85mL ethanethiol, and 19.6mL propylene sulfide and 
reacted for 90 minutes on ice. Under these conditions, a target molecular weight of 740 
g/mol would be achieved at 100% conversion. The product was end capped by reacting 
with 10 mole equivalents N-(2-bromoethyl)-phthalimide (13.4 g) to yield PPS-
phthalamide (PPS-Phth). PPS-Phth was deprotected to yield a free amine by dissolving 
in ethanol and refluxing overnight at 80 ˚C in the presence of 3 mole equivalents 
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hydrazine hydrate and under argon atmosphere. The resultant polymer was dissolved in 
methylene chloride and precipitated into cold hexane 5 times and then dried overnight in 
vacuo. The final polymer product appeared as a viscous pale yellow liquid at this stage. 
PS-Phth and PPS-NH2 were characterized by nuclear magnetic resonance (NMR) and 
gel permeation chromatography (GPC) for composition, molecular weight and 
polydispersity. GPC (Agilent) was used to determine molecular weight and 
polydispersity (Mw/Mn, PDI) of the PPS-Phth and PPS homopolymers using HPLC-
grade dimethylformamide (DMF) containing 0.1% LiBr at 60°C as mobile phase. 
Molecular weight calculations were conducted with ASTRA V software (Wyatt 
Technology) and were based on calculated dn/dc values for PPS-Phth determined 
through injection of serial dilutions of the polymer in conjunction with off-line refractive 
index monitoring. 
To create diblock copolymers of NH2-PEG-PPS, PPS-NH2 was functionalized by 
reacting with 1.2 eq of N-Succinimidyl iodoacetate in DMF overnight at room 
temperature in the dark. The resulting PPS-N-Hydroxysuccinimide was then precipitated 
in cold diethylether and dried in vacuo and appeared as a dark red viscous liquid. Care 
was taken to avoid excess exposure to light. This product was then reacted by mixing 
with 1eq NH2-PEG-SH (3400M.W. from Laysan Bio; Arab, AL) under an inert 
atmosphere for 24 hours at room temperature (Scheme 1). PEG-PPS was confirmed by 
NMR in anhydrous D6MSO and GPC. 
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Scheme 1. PEG-PPS synthesis scheme. Step 1 is polymerization of Phth terminated 
PPS, step 2 is deprotection of the PPS-Phth to yield PPS-NH2, step 3 is conjugation of 
PPS-NH2 with the thiol terminus of SH-PEG-NH2. 
PEG-PPS micelle formation 
Micelles were formed by a direct hydration method. PEG-PPS polymers and USPIOs 
were dissolved at a 1.5 polymer:USPIO ratio into a small amount of anhydrous 
dimethylsulfoxide (DMSO) and added to PBS without calcium and magnesium drop-
wise at a rate of 8 mL.hour-1 to a final polymer concentration of 2 mg.mL-1. Next, excess 
USPIOs were removed by pelleting on a strong magnet and centrifuging at 3500 xg for 
5 min and filtered through a 0.45 μm PTFE syringe filter. Micelles were characterized by 
dynamic light scattering (DLS), zeta potential, transmission electron microscopy (TEM), 
and MRI. For TEM, non USPIO containing samples were prepared by negative staining 
with uranyl acetate. DLS and zeta potential measurements were performed using a 
Malvern Zetasizer Range at a concentration of 100 ug.mL-1. For MRI analysis, USPIO 
polymer samples were prepared by serial dilution from 2 mg.mL-1 stocks, loaded into 5 
mm NMR tubes, and imaged using a 4.7 T Varian small animal MRI with a 31 cm bore. 
Molar relaxivity (r2) values were calculated based on a linear regression of R2 values 
dependent on the polymer concentration in the samples. 
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Peptide functionalized micelle synthesis 
Peptide conjugation to H2N-PEG-PPS was performed by activation of the carboxyl 
terminus with 4eq of N-Hydroxysuccinimide in the presence of 4 molar equivalents 
dicyclohexylcarbodiimide (DCC) in DMSO. The reactants were dissolved separately in a 
small amount of DMSO and degassed for 30 minutes under constant nitrogen flow. 
Following degassing, the reagents were mixed together by syringe addition. The 
reaction was brought to 0 ˚C on ice for 4 hours and allowed to proceed overnight at 
room temperature. The resulting Peptide-NHS was precipitated into cold dietheylether 
five times and dried under vacuum. To perform conjugation the NHS-Peptide and H2N-
PEG-PPS were mixed in anhydrous DMSO and allowed to react for 48 hours. This 
product was precipitated five times into cold diethyl ether and then dried in vacuo. Next, 
the Fmoc protecting group was removed from the N-terminus of the peptide by reaction 
with 20% piperidine in N-Methyl-2-pyrrolidone (NMP) for 20 minutes, and then 
precipitated again into cold diethyl ether and dried in vacuo. The resultant peptide-
polymer conjugates were purified by dialysis against DMSO for 24 hours and 
subsequently water for 48 hours. The dialyzed product was then lyophilized.  
Mixed micelle characterization 
Mixed micelles of Peptide-PEG-PPS were then tested for size and stability. Micelles 
were formed as previously described with varying ratios of Peptide-PEG-PPS to H2N-
PEG-PPS (75, 50, and 25%). The sizes of mixed micelles were then measured by DLS 
following the same method to characterize H2N-PEG-PPS micelles. 
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MRI imaging of atheroprone vasculature 
For MRI experiments, mice were injected with nanoparticles at four days post ligation at 
a dose of 10mg.kg-1 polymer. Injections were performed immediately before imaging. 
MRI was performed at 7.0 Tesla using a 35mm bird cage coil and mouse cradle. Mice 
were anesthetized with a 4% isoflurane in air mixture before being maintained under 
anesthesia with 1.5-2% isoflurane in air mixture. Isoflurane concentration was adjusted 
to maintain a respiration rate of 40-60 breaths per minute. Two MRI pulse sequences 
were utilized for T2 and T2* weighted contrast, and pulse acquisition was respiration 
gated to minimize movement artifacts. 
Targeted liposome synthesis and characterization 
The phage displayed peptide Acetyl-GSPREYTSYMPHGSGS-COOH (PREY) and the 
scrambled control peptide Acetyl-THRPMSSYEPGYGSGS-COOH (Scrambled PREY) 
were conjugated to 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-
(hexanoylamine) (DPHE, Avanti Polar Lipids, Alabaster, AL, Cat# 870125C) to form 
targeted liposomes by anhydrous NHS-DCC reaction (Scheme 2). Two molar 
equivalents of the acetylated peptide was added to 4 eq. DCC and NHS and mixed with 
1 eq. DPHE dissolved in a 1:1 mixture of anhydrous DMF and anhydrous methanol 
under nitrogen at room temperature. Two molar equivalents triethylamine in DMF was 
added to the reaction to act as a catalyst. The reaction was allowed to proceed 
overnight, however, robust precipitation of dicyclohexylurea was observed after 30 
minutes. Dicyclohexulurea is a reaction product of DCC coupling and indicates 
progression of the reaction. The reaction product was filtered through a 0.45 µm PTFE 
filter to remove insoluble products, precipitated twice into cold diethylether and dried in 
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vacuo. Reaction products were then dissolved in a 65/35/8 mixture of 
chloroform/methanol/water, diluted into water, and purified by flash chromatography 
over disposable octadecyl C18 columns (Bakerbond spe, Avantor Performance 
Materials, Center Valley, PA, Cat# 720-06). Purified peptide-DPHE products were 
eluted with 100% methanol, precipitated into cold diethylether, and dried in vacuo. 
Reaction products were confirmed by ESI-MS. 
 
Scheme 2. DHPE conjugation to peptides. The NH2 terminus of the DPHE is 
conjugated to the COOH terminus of acetylated peptides by DCC/NHS coupling. 
Liposomes were formed using a 97.6:2.4 molar ratio of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC, Avanti Polar Lipids, Cat# 850355C) and AcPEPTIDE-DPHE 
conjugates. 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine Perchlorate (DiD) 
or 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide (DiR) were added to 
the liposome mixture as a fluorescent tracer. To form liposomes, 2.08 µmol DPPC (25 
mg.mL-1 in chloroform), and 0.052 µmol AcPEPTIDE-DPHE (12.5 mg.mL-1 in methanol), 
and either 0.15 µmol DiD (25 mg.mL-1 in methanol) or 0.14 µmol DiR (25 mg.mL-1 in 
methanol) were combined mixed well in a 13 x 100 mm glass test tube, dried under 
nitrogen and subsequently in vacuo for at least two hours. The mixture was re-
suspended in 1.3 mL hanks buffered saline (HBS) solution containing 100 mM NaCl, 20 
mM Hepes/NaOH pH 7.5 and 0.02% w/v sodium azide and sonicated for 1.5 hours to 
yield a 1.6 mM liposome solution containing 0.12 mM DiD or DiR. DiD containing 
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liposomes were used for confocal imaging, and DiR containing liposomes were used for 
flow cytometry, IVIS imaging, and liposome characterization experiments. 
The hydrodynamic diameter was characterized on a Malvern Zetasizer Nano-ZS 
(Malvern Instruments Ltd., Worcestershire, U.K.). 
Whole blood compatibility 
Whole blood compatibility of the liposomes was determined by performing a whole 
blood aggregation assay as previously described [244]. Targeted liposomes were 
formed as previously described at 1.6 mM concentration in HBS. Serial dilutions of the 
liposomes were then added to human whole blood at a final liposome concentration of 
1, 0.1, and 0.01 mM.  As a control, the micelles were also added to HBS at the same 
concentration.  Blood-liposome mixtures were placed on a shaker for 5 minutes and 
incubated at 37°C for an hour. The plates were then centrifuged at 500 ×g for 5 
minutes. One hundred μL of supernatant from each well was transferred to a black, 
clear bottom 96-well plate and DiR fluorescence was measured with excitation λ= 750 
nm and emission wavelength λ= 780 nm on a TECAN Infinite M1000 Pro plate reader 
(Tecan Group Ltd, Mannedorf, Switzerland). 
Liposome injections 
For liposome localization and targeting experiments, liposome solutions were 
administered to mice by intravenous injection through the tail vein four days after partial 
carotid ligation at a concentration of 0.9 mg fluorophore per kg body weight. Fifteen 
hours post injection mice were euthanized by CO2 inhalation, and perfused with 
heparinized saline as described previously. Arteries were then analyzed for liposome 
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uptake by flow cytometry, IVIS imaging, and confocal microscopy. Liposome uptake 
was compared between LCA and RCA using scrambled peptide-targeted liposomes as 
a control. 
Flow cytometry 
To obtain single cell suspension solutions from sample arteries, carotid arteries were 
surgically removed and placed into a digestion solution consisting of phenol red free 
RPMI 1640 medium (Life Technologies, Grand Island, NY) with L-glutamine, 10% fetal 
bovine serum, 1 mg.ml-1 collagenase A, 1 mg.ml-1 collagenase B, and 0.1 mg.ml-1 
DNAse 1 (Roche Diagnostics, Indianapolis, IN Cat# 10103578001, 11088807001 and 
10104159001, respectively). The arteries were minced with sharp scissors for two 
minutes and then placed on a shaker for 30 minutes at 37 ˚C. Next, the arteries were 
filtered using a 70 µm cell strainer to obtain cell suspensions. The cell strainer was 
washed three times with 10 mL RPMI 1640 to recover dissociated cells. Next, the cells 
were centrifuged at 300 xg for 10 minutes and then transferred to FACS tubes for the 
rest of processing. All subsequent steps took place in FACS buffer consisting of 1x PBS 
with Ca2+ and Mg2+, 1% bovine serum albumin and 0.1% sodium azide. The cell 
samples were first processed by blocking Fc receptors with CD16/CD32 for 10 min at 
4°C (BDbiosciences, clone 2.4G2, Cat# 553142) for 10 minutes on ice. The cells were 
centrifuged at 300 xg for 5 minutes and washed once with 1 mL of FACS buffer. Cell 
populations were characterized by Brilliant Violet 510 (BV510)-conjugated anti-CD45 
antibody (BioLegend, clone 30-F11, Cat# 103137), phycoerythrin-conjugated anti-CD31 
antibody (BD pharmingen, clone MEC13.3, Cat# 561073), and fluorescein 
isothiocyanate-conjugated anti-Ly-6A/E (Sca1) antibody (BD Pharmingen, clone E13-
161.7, Cat# 553335). CD31 was considered a marker for endothelial cells, CD45 as a 
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marker for all leukocytes, and Sca1 as a marker for stem cells [245]. Cells were 
incubated with staining solutions for 30 minutes at 4 ˚C and then washed twice with 
FACS buffer. For dead cell staining, 7-aminoactinomycin-D (7-AAD) (eBioscience, Cat# 
00-6993-50) was added to cells 10 minutes prior to sorting. Acquisition of minimum of 
500,000 events was on BD FACS Canto II™ system (8-color, blue, red, violet, Cat# 
338962), and analysis was performed on BD FACSDiva software version 6.1.3 (BD 
Biosciences). 
Gating was applied based on the single stain and flow minus one controls. Dead cells 
and cell clumps were excluded by gating on 7-AAD and then for single cells based on 
forward scatter area vs. forward scatter height. 
Confocal microscopy 
For confocal microscopy experiments, liposomes were formulated with DiD. For all 
imaging experiments, mice were euthanized by CO2 asphyxiation 15 hours post 
injection, and perfused with heparinized saline as described previously. For aortic arch 
samples mice were subsequently perfused at physiological pressure with 10% neutral 
buffered formalin for 5 minutes and then dissected to isolate a tissue block containing 
the heart, lungs, and whole aorta. Tissue blocks were further fixed in 10% buffered 
formalin for 24 hours, and subsequently paraffin-embedded and sectioned at 5 µm. The 
Vanderbilt Translational Pathology Shared Resource performed all embedding and 
sectioning. For carotid artery samples, the carotid arteries were surgically isolated, 
cannulated with 30-gauge syringe, and washed with TBST. Next, arteries were cut 
longitudinally to expose the endothelium, and mounted on microscope slides with 4% 
paraformaldehyde in PBS without Ca2+ and Mg2+. Carotid artery samples were 
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counterstained with Hoechst to visualize nuclei. Fluorescence images were acquired 
using a Zeiss 710 confocal laser microscope. 
RESULTS AND DISCUSSION 
Studies with peptide targeted micelles 
PPS-Phth was successfully synthesized as described previously. GPC analysis 
demonstrated a dn/dc = 0.1244 +/- 0.0018 mL/g. PPS-NH2 was successfully 
synthesized having a molecular weight of 846 Da as determined by NMR and a 
polydispersity of 1.32 +/- 0.096 as determined by GPC. PEG-b-PPS synthesis was 
confirmed by NMR.  
PEG-PPS micelles were found to have a diameter of 149.27 ± 57 nm by dynamic light 
scattering and 169.53± 55 nm by TEM (Figure 1A). USPIO loading in micelles was 
confirmed by TEM and zeta potential measurements. TEM showed a drastic increase in 
the electron density of the micelles after USPIO loading (Figure 1B). Loading USPIOs 
into polymeric micelles caused a shift in the zeta potential from negative to nearly 
neutral, demonstrating a shielding of the negative charge of the oleic acid stabilizing 
layer by the polymeric micelles (Figure 1C). The nearly neutral zeta potential is also a 
requirement for intravascular delivery [246]. 
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Figure 1. Characterization of PEG-PPS-USPIO micelles. A) TEM of PEG-PPS micelles 
demonstrated a diameter of around 170 nm. B) Encapsulation of USPIOs in PEG-PPS 
micelles causes an increased electron density in the core of the micelle structure, which 
indicates successful encapsulation. C) Charge shielding of negatively charged USPIOS 
was demonstrated by zeta potential measurements, which further confirmed USPIO 
encapsulation in PEG-PPS polymer micelles. 
MRI demonstrated that loaded polymeric micelles have a molar relaxivity of 6.76 mM-1.s-
1 relative to the concentration of polymer in the sample (Figure 2). This relaxivity can 
give a reasonable signal to noise ratio for in vivo targeting of these nanoparticles [235].  
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Figure 2. USPIO loaded PEG-PPS micelle molar relaxivity. The slope of the 
concentration versus transverse relaxation gives the molar relaxivity of the PEG-PPS-
USPIO nanoparticles. The inset shows heatmap of transverse relaxivity taken as a 
cross section of nanoparticle samples in the MRI. 
Mixed micelles of 25 and 50% DistL12-PEG-PPS, and FAM-PREY-PEG-PPS content 
were found to be stable in PBS at a concentration of 100 mg.mL-1. Micelles of 75% 
DistL12-PEG-PPS, 25% PEG-PPS and 75% FAM-PREY-PEG-PPS, 25% PEG-PPS 
content were found to destabilize at the same concentration (mg.mL-1) as evidenced by 
the formation of large aggregates during DLS measurements (Figure 3). Due to the 
destabilizing effect of the DistL12 peptide, 20% DistL12-PEG-PPS and FAM-PREY-
PEG-PPS containing micelles were used for MRI imaging experiments.  
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Figure 3. Mixed micelle stability. Increasing Peptide-PEG-PPS concentration resulted in 
a destabilization of the mixed micelles with both DistL12 and PREY peptides as 
evidenced by the formation of large aggregates and changes in micelle hydrodynamic 
diameter.  
The results of this experiment using the DistL12 and FAM-PREY targeted nanoparticles 
are shown in figure 4. The T2* image using a bright blood Fast Low Angle Shot 
(FLASH) sequence shows the left carotid arteries and jugular veins clearly. I was not 
able to identify any signal decay as a result of iron oxide nanoparticle accumulation in 
the carotid arteries. Potential issues include renal clearance, low concentrations of iron 
oxides, and instability of PEG-PPS-USPIO nanoparticles. Published values for similar 
studies indicate dosages of around 5-30 mg.kg-1 of iron injected and the concentration 
that was used for this study was 10 mg.kg-1 [179, 247]. Another potential issue with 
these nanoparticles is instability in blood. The core block polymer synthesized was 
around 850 Da while the PEG block was 3500 Da. Generally, amphiphilic polymers 
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synthesized for micelle applications should have a hydrophobic core block around 2 
times the molecular weight of the hydrophilic block. Based on these results, PEG-PPS-
USPIO nanoparticles were not pursued as a delivery platform. 
 
Figure 4. MRI images after targeted micelle injection. Accumulation of USPIOs should 
result in a signal drop (dark region). No noticeable signal drop was observed for either 
peptide candidate investigated. 
Studies with peptide targeted liposomes 
Peptide-targeted liposomes were found to have an average hydrodynamic diameter of 
64 nm with a polydispersity of 0.295 by dynamic light scattering (Figure 5A). This size of 
liposome is inside the acceptable size range for vascular delivery of nanoparticles [248]. 
When incubated with whole blood or in buffer, I observed no difference in liposome 
stability (Figure 5B). These results indicate that targeted liposomes are compatible with 
blood and suitable for vascular delivery.  
78 
 
Figure 5. Liposome characterization. A) DLS measurements of targeted liposomes 
showed a hydrodynamic diameter of 64 nm and a polydispersity of 0.295. B) Whole 
blood compatibility of liposomes showed no difference between liposomes incubated in 
whole blood versus buffer, indicating that liposomes are stable in blood. 
When injected into mice, liposomes accumulated in the spleen and liver, with negligible 
accumulation in the heart, lungs, kidneys, and other tissues (Figure 6). This 
biodistribution is characteristic for clearance of liposomes with similar composition, and 
also indicates a low risk for cardiac or pulmonary toxicity [249].  
 
Figure 6. Liposome biodistrubution measured by IVIS. A) Liposome injection B) No 
liposome injection. These results demonstrated clearance routes similar to other 
liposomes of comparable physical characteristics. 
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To visualize nanoparticle targeting to atheroprone vasculature, liposome solutions (0.9 
mg fluorophore per kg body weight, 1.6 mM lipids in HBS) were administered to mice by 
intravenous injection through the tail vein four days after the partial ligation procedure. 
Fifteen hours post injection, mice were euthanized and arteries were analyzed for 
liposome targeting. Liposome uptake was compared between LCA and RCA using 
scrambled PREY-conjugated liposomes as a control. 
Figure 7A shows en face preparations of ligated left carotid arteries after liposome 
injection. I found that PREY-targeted liposomes accumulate in the partially ligated LCA 
(Figure 7A, bottom) while scrambled PREY-conjugated liposomes showed minimal 
uptake in the ligated vessel (Figure 7A, top). I also investigated uptake of targeted 
nanoparticles in the lesser curvature of the aortic arch, another vascular location known 
to have disturbed flow [67]. Figure 7C shows a cross section of the aortic arch of a 
mouse after liposome injection. I observed accumulation of PREY targeted liposomes in 
the lumen at the inner curvature of the aortic arch in mice without partial carotid ligation 
surgery. These results demonstrate that PREY-targeted liposomes home to natural 
regions of disturbed flow in vivo. 
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Figure 7. En face preparations of ligated left carotid arteries with scrambled and 
targeted liposome injections. Red = liposome fluorescence, blue = nuclei, Green = 
Elastin autofluorescence, scale bars = 100 µm. D) Cross section of a mouse aortic arch 
showing targeted liposome accumulation in the lesser curvature of the aortic arch 
(inset). Green = elastin autofluorescence, Red = Liposome fluorescence, scale bar = 
250 µm, inset scale bar = 100 µm. 
Next I sought to determine the vascular cell type targeted by PREY liposomes. To do 
this, I performed flow cytometry on arteries after liposome injection. Single cell 
suspensions from the LCA and RCA were co-stained with platelet endothelial cell 
adhesion molecule (CD31) as a marker for endothelial cells, protein tyrosine 
phosphatase receptor type C (CD45) as a marker for all leukocytes, and stem cell 
antigen-1 (Sca1) as a marker for stem cells which are known to reside in the vascular 
adventitia [245]. Dead cells and cell clusters were excluded from analysis. This analysis 
showed that PREY-targeted liposomes accumulate in CD31+ endothelial cells 
significantly more than scrambled PREY-conjugated liposomes (Figure 8A). Increased 
uptake of liposomes in the left carotid artery was also observed in CD45+ and Sca1+ 
cells; however, no significant difference was observed between PREY and scrambled 
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PREY liposomes (Figure 8B, C). This is likely due to nonspecific uptake of liposomes by 
these cell types, which are known to accumulate in vasculature with activated 
endothelium. 
 
Figure 8. Flow cytometry analysis of cellular targeting. A) CD31+, CD45- cell population 
B) CD45+ cell population C) Sca1+ cell population. These results demonstrate 
significantly greater uptake of PREY targeted liposomes compared to scrambled PREY 
liposomes in endothelial cells but not leukocytes of stem cells.  
CONCLUSIONS 
Atherosclerotic lesions develop when focal endothelial dysfunction caused by 
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disturbed shear stress is compounded by systemic risk factors such as 
hypercholesterolemia. Targeted drug delivery to areas of disturbed flow is a 
promising approach to prevent atherosclerosis before lesions develop. Because 
prediction of these atheroprone areas is speculative, programming nanocarrier 
functions to navigate to and detect atheroprone areas is an ideal but unmet need. I 
accomplished this with peptides discovered by in vivo phage display and 
functionalized two nanoparticle candidates; PEG-PPS-USPIO nanoparticles for MRI 
imaging, and liposomes for drug delivery.  
PEG-PPS polymers were successfully synthesized and were found to encapsulate 
USPIOs in 160 nm micelles. These USPIO loaded PEG-PPS nanoparticles were 
functionalized with two peptide candidates from in vivo phage display to form 
targeted nanoparticles for MRI imaging of atheroprone vasculature. In vivo injections 
of the nanoparticles were performed and did not result in discernable signal drop in 
the targeted LCA. Additionally, the drug candidate used in aim 3 is hydrophilic and 
PEG-PPS-USPIO nanoparticles are not able to encapsulate hydrophilic drugs. 
Based on the results of studies with PEG-PPS-USPIO nanoparticles, they were 
abandoned as theranostic delivery platforms for the remainder of my work. 
PREY-functionalized liposomes were synthesized with a diameter of around 65 nm 
and were shown to be stable in whole blood. I also demonstrated that PREY-
targeted liposomes accumulate in areas of disturbed shear in vivo. Using flow 
cytometry, I showed that PREY-targeted liposomes home to endothelial cells in 
atheroprone vasculature, making this nanocarrier a promising candidate for drug 
delivery to treat endothelial dysfunction. In the next experiments, I demonstrated 
drug delivery to areas of disturbed flow in vivo using the PREY-targeted liposomes 
83 
developed in this aim. 
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CHAPTER IV 
 
TARGETED DELIVERY OF THERAPEUTIC LIPOSOMES 
 
INTRODUCTION 
Oxidative stress is a major cause of endothelial dysfunction in diseases such as 
atherosclerosis, hypertension and diabetes [9, 10]. Previous studies have shown that a 
major source of reactive oxygen species in endothelial cells exposed to disturbed flow is 
uncoupled nitric oxide synthase [28]. Tetrahydrobiopterin (BH4) is a critical co-factor for 
the NO synthases. BH4 permits transfer of electrons from the prosthetic heme group to 
the guanidino-nitrogens of L-arginine, allowing formation of NO. In the absence of BH4, 
electrons from the NOS heme group reduce oxygen to produce superoxide. Disturbed 
shear on endothelial cells results in an uncoupling of the eNOS enzyme while laminar 
shear causes a 2 fold increase GTPCH-1 phosphorylation and increases its activity 30 
fold. This increases the synthesis of BH4, while it is deficient in endothelial cells exposed to 
oscillatory shear stress [33, 127]. BH4 oxidation to inactive BH2 also occurs in endothelial cells 
exposed to disturbed flow and further depletes intracellular BH4. In the partial carotid ligation 
model, studies have confirmed that BH4 levels are reduced, and that oral supplementation of 
BH4 can recouple NOS and abrogate the accelerated atherosclerosis that occurs in the ligated 
artery [28, 57, 153]. Challenges associated with delivery of exogenous BH4 include oxidation 
and poor cellular uptake in endothelial and parenchymal cells [62]. BH4 is also a cofactor for the 
synthesis of catecholamines, which could lead to unexpected effects on neurological and 
vascular function if administered systemically [33]. I therefore sought to use the PREY-targeted 
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liposomal nanocarriers to protect BH4 from oxidation in circulation and deliver BH4 to endothelial 
cells in atheroprone regions. 
APPROACH 
Previous experiments demonstrated that PREY-targeted liposomes home to endothelial 
cells in regions of disturbed flow, making them an ideal candidate to deliver therapeutics 
to dysfunctional endothelium. Studies have also shown that delivery of BH4 can rescue 
endothelial dysfunction in response to disturbed shear stress. In this aim, I sought to 
deliver BH4 using PREY-targeted liposomes. We examined the delivery of BH4 to target 
tissue, and measured superoxide as a functional readout of endothelial dysfunction. In 
additional experiments, I investigated the effect of PREY-liposome BH4 delivery on 
endothelium dependent relaxation and plaque formation in ApoE-/- mice. 
METHODS 
Tetrahydrobiopterin (BH4) encapsulation and protection from oxidation  
BH4 was encapsulated in liposomes by a thin film rehydration technique [250]. First, 
lipids in organic solvent were dried as previously described. Immediately before 
formation of liposomes, BH4 was dissolved in HBS at 17 mM. Lipids were then 
reconstituted in 17 mM BH4 in HBS, and sonicated for 1.5 hours to form liposomes. We 
tested the encapsulation efficiency by dialyzing liposome solutions overnight against 
HBS buffer using 3500 molecular weight cutoff cellulose acetate dialysis tubing and 
measuring BH4 concentrations post-dialysis (Spectrum labs, Grand Rapids, MI). BH4 is 
commonly administered with L-ascorbic acid as an antioxidant, therefore, I also tested 
co-encapsulation of BH4 with L-ascorbic acid, by adding 0.04% L-ascorbic acid to HBS 
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buffer before addition of BH4 [57]. Because BH4 rapidly oxidizes in physiological 
conditions, the ability of the liposomes to protect BH4 from oxidation was examined. 
Liposomes formed with BH4 were incubated at 1.7 mM in 50% FBS in HBS. Samples 
were collected at 30 minutes and 24 hours to determine the amount of BH4 remaining in 
solution. 
Nanoparticle delivery of BH4 
Liposomes containing BH4 were administered one-day post ligation by tail vein injection 
at 0.9 mg fluorophore per kg body weight. Animals studied included apolipoprotein E 
knockout (ApoE-/-) and C57/BL6J mice. Seven days post ligation, animals were 
sacrificed and endpoint analysis performed. 
Quantification of BH4 
BH4 concentrations were measured by HPLC as previously described [28, 251]. To 
analyze arterial levels of BH4, seven days post ligation mice were sacrificed by CO2 
inhalation and perfused with ice cold heparinized PBS. Carotid arteries were surgically 
isolated, and care was taken not to stretch or damage the arteries. Carotid arteries were 
then snap frozen in liquid nitrogen. To obtain artery homogenate, carotid arteries were 
ground using a mortar and pestle pre-cooled on dry ice. Artery homogenate was then 
dissolved in 110 µL lysis buffer (50mM Tris-HCl, pH 7.4, 1 mM  dithiothreitol, and 1 mM 
ethylenediaminetetraacetic acid) and 12.5 µL of a 1:1 mixture of 1.5 M HClO4 with 2 M 
H3PO4 was added to precipitate proteins. Samples were then centrifuged at 13,500 g for 
2 minutes at 4 °C. Next, differential oxidation was performed in acid and alkaline 
preparations. BH4 was detected by fluorescence (Ex. 350 nm Em. 450 nm) at a 
retention time of 9.5 minutes using a 5 x 250 mm x 5 um C18 column was used with an 
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isocratic solvent system consisting of 95% water with 5% methanol at a flow rate of 1 
mL.min-1. Concentrations were normalized to protein content as measured by BCA 
assay according to manufacturer’s protocol. 
Measurement of superoxide 
To evaluate the effect of nanoparticle treatment on vascular ROS production, 2-
hydroxyethidium formation from dihydroethidium (DHE) was measured by HPLC as 
previously described [252]. To measure arterial superoxide, 7 days post ligation mice 
were sacrificed by CO2 inhalation and perfused with ice-cold Krebs-HEPES buffer 
containing 99 mM NaCl, 4.69 mM KCl, 25 mM NaHCO3, 1.03 mM KH2PO4, 5.6 mM D(+) 
Glucose, 20 mM Na-HEPES, 2.5 mM CaCl2 x 2H2O, and 1.2mM MgSO4 x 7H2O. 
Carotid arteries were surgically isolated and care was taken not to stretch or damage 
the arteries. Each carotid artery was placed on 1 mL ice-cold krebs-HEPES buffer and 
carefully trimmed to remove adventitial fat. Each artery was then cut into 5 equally sized 
rings. A 5 µM stock solution of DHE in anhydrous DMSO was created by degassing 
DMSO under nitrogen for 30 minutes and adding to fresh DHE. 5 µL of this stock 
solution was added to each artery, and the samples were incubated in the dark at 37 °C 
for 30 minutes. Next, the artery rings were placed in 300 µL ice-cold methanol and 
homogenized using a dounce homogenizer. Samples were then filtered through 0.2 µm 
PTFE filters and stored at -80 °C in the dark until running. 2-hydroxyethidium was 
detected by fluorescence (Ex. 480 nm, Em. 580 nm) at a retention time of 13.5 minutes 
using a 4.5 x 250 mm reverse phase C18 column (Nucleosil, Sigma-Aldrich, St. Louis, 
MO) and a mobile phase of 60% acetonitrile with 0.1% trifluoroacetic acid with a linear 
increase in acetonitrile concentration from 37% to 47% over 23 minutes at a flow rate of 
0.5 mL.min-1. 
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Endothelium dependent relaxation 
To quantify endothelium dependent relaxation, 7 days post ligation carotid rings from 
the ligated LCA of ApoE-/- animals were subjected to isometric tension studies using a 
multi-wire myograph system. Artery rings were equilibrated for 30 minutes with in 
myography buffer, pre-constricted using phenylephrine, and then exposed to increasing 
concentrations of acetylcholine to assess endothelium dependent vasodilation. 
Endothelium independent relaxation in response to NO donor sodium nitroprusside was 
also examined [153].  
Quantification of plaque burden in ApoE-/- mice 
ApoE-/- mice received the partial carotid artery ligation surgery and were immediately 
fed a western diet (Teklad #88137, 42% from fat, Harlan Laboratories, Indianapolis, IN) 
[253]. Seven days post ligation mice were sacrificed by CO2 inhalation. Mice were then 
perfused with ice-cold heparinized saline and then perfused at physiological pressure 
with 10% neutral buffered formalin. Next, carotid arteries were surgically removed, 
cleaned of excess adventitial fat, and mounted in optimal cutting temperature (OCT) 
mounting medium (TissueTek, VWR, Radnor, PA). Cryosections were obtained at 5 µm 
thickness. Sections were stained with Hematoxylin and Eosin. To quantify plaque 
burden, lumen area was traced and plaque area expressed as a percentage of the total 
lumen area. Average lumen area covered was calculated for N=4 animals per group. 
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Serum lipid analyses 
Blood was collected into a heparinized syringe by cardiac puncture after sacrifice. The 
serum total cholesterol and triglyceride levels were determined in serum samples using 
enzymatic assays (Roche). Fast performance liquid chromatography was performed on 
an HPLC system model 600 (Waters, Milford, MA) using a Superose 6 column 
(Pharmacia, Piscataway, NJ) in both groups of samples (n=4 and n=4). 
RESULTS AND DISCUSSION 
I sought to determine if PREY-targeted nanoparticles could be used for drug delivery to 
improve endothelial function in atheroprone areas under disturbed flow. BH4 was 
encapsulated in liposomes by a thin film rehydration technique [250]. BH4-containing 
liposomes were found to have the same hydrodynamic diameter of 65 nm as liposomes 
prepared without BH4. I measured the encapsulation efficiency of BH4 by dialyzing 
liposomes formed with BH4 for 18 hours and measuring BH4 concentration remaining by 
HPLC. These experiments demonstrated a loading efficiency of around 6%. This 
loading efficiency is expected for the encapsulation technique used [250, 254, 255]. In 
addition, it is possible that some BH4 is oxidized during dialysis, and therefore the 
resulting BH4 measured after dialysis could result in artificially lower encapsulation 
efficiency. In addition, incorporation of L-ascorbic acid as an antioxidant buffer 
destabilized the liposomes and resulted in zero encapsulation. Based on these results, 
for all the following experiments I used liposome encapsulated BH4 as formed, without 
addition of L-ascorbic acid and without overnight dialysis. In this setting, I found that 
liposome encapsulated BH4 was significantly more stable than free BH4 over 24 hour 
incubation in 50% serum (Figure 1). This result demonstrated that liposome stability 
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was not compromised by encapsulation of BH4 and that liposomes could be used to 
deliver BH4 to target tissues.  
 
Figure 1. Liposomes maintained the stability of BH4 in serum significantly more than un-
encapsulated BH4 after 24 hours, indicating the ability of liposomes to encapsulate and 
protect BH4 from oxidation. †, p = 0.017. 
To determine if targeted nanoparticles could increase BH4 concentration in target tissue, 
targeted nanoparticles containing BH4 were injected by tail vein one-day post ligation in 
wild-type mice and the carotids were removed for measurement of pterins seven days 
later. PREY targeted nanoparticles were found to significantly increase BH4 
concentration in target tissue compared to scrambled PREY controls (Figure 2). In mice 
without liposome treatment, BH4 levels in the ligated artery are around 50% of the 
unligated artery. In these experiments scrambled PREY liposomes resulted in a modest 
increase in BH4 in the ligated artery. This is likely due to uptake of scrambled PREY 
liposomes by monocytes in the ligated artery, as observed in flow cytometry 
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experiments from aim 2. Earlier experiments showed that PREY-targeted liposomes 
selectively target endothelial cells in the ligated LCA. Because eNOS is the dominant 
NOS isoform in vasculature, I reasoned that increases in BH4 in the PREY targeted 
group were largely delivered to endothelial cells. BH4 delivery to endothelial cells would 
reduce total vascular superoxide resulting from recoupling of eNOS, therefore I next 
measured vascular superoxide after nanoparticle delivery.  
 
Figure 2. Liposome delivery significantly increased BH4 concentration in the ligated 
artery with targeted liposomes but not with scrambled controls. This result indicates the 
efficacy of PREY-targeting in delivering BH4 to atheroprone arteries. 
I measured superoxide levels in carotid arteries by monitoring the conversion of DHE to 
its superoxide adduct, 2-hydroxyethidium. PREY-targeted liposome delivery of BH4 
significantly decreased superoxide in the ligated artery compared to scrambled peptide 
controls (Figure 3). In animals without liposome treatment, superoxide levels are around 
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2 times greater in the ligated artery. This trend is mirrored by scrambled PREY 
liposomes in this experiment. Combined with a modest increase in BH4 levels in the 
ligated artery in scrambled PREY treated animals, this result further confirms that 
increased BH4 observed from scrambled PREY liposomes were due to uptake by 
immune cells in the ligated artery. These results indicate that targeted delivery of BH4 
can successfully increase the availability of this critical cofactor in endothelial cells and 
reduce oxidative stress in ligated arteries resulting from uncoupled nitric oxide synthase.  
 
Figure 3. Liposomal delivery of superoxide significantly decreased superoxide 
concentration in the ligated artery with targeted liposomes but not with scrambled 
controls. This result indicates the ability of PREY-targeted delivery of BH4 to reduce 
oxidative stress caused by eNOS uncoupling. 
To determine if targeted BH4 delivery can prevent vascular dysfunction in response to 
disturbed flow and hypercholesterolemia, ApoE-/- mice underwent partial carotid artery 
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ligation surgery and were fat fed to induce atherosclerosis [253, 256]. This model leads 
to accelerated atherosclerotic lesions after one week of high fat diet [74]. Mice received 
nanoparticle injections at one-day post ligation and endpoint experiments were 
conducted at seven days post ligation.  
I first measured endothelium dependent relaxation as a measure of endothelial 
dysfunction. In these animals, carotid ligation results in uncoupled eNOS in the ligated 
artery, which should impair endothelium dependent relaxation in response to 
acetylcholine. In animals treated with PREY-targeted liposomes I observed improved 
endothelium dependent relaxation compared to scrambled controls (Figure 4). This 
result further confirmed that liposomal delivery of BH4 rescues eNOS uncoupling and 
improves endothelial function, even in the case of severe hypercholesterolemia.  
 
Figure 4. Endothelium dependent relaxation in ApoE-/- mice 7 days post ligation. This 
result indicates that PREY-targeted delivery of BH4 improves endothelial function in the 
ligated artery. Scrambled EC50 = -6.813 to -5.169 Targeted EC50 = -7.514 to -6.277.  
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As another functional readout of effective targeted liposome treatment, I measured 
lumen area in the same ApoE-/- model. I found a significant decrease in plaque burden 
in the ligated left carotid artery of mice that received PREY-targeted liposome injections 
compared to scrambled controls (Figure 5).  
 
Figure 5. Liposomal delivery of BH4 significantly reduced plaque burden in the ligated 
left carotid artery of ApoE-/- mice fed a high fat diet for 7 days. Plaque area 
quantification shows that PREY-targeted delivery of BH4 prevents formation of lesions in 
the ligated artery of ApoE-/- mice fed a high fat diet for 7 days. 
In order to determine if reduction in plaque area was due to altered lipid metabolism, I 
measured plasma lipids in mice receiving PREY and scrambled PREY liposomes 
containing BH4. BH4 containing PREY-targeted liposomes did not significantly alter total 
cholesterol or triglycerides in these animals compared to scrambled PREY controls 
(Figure 6). This indicates that nanocarrier delivery of BH4 prevents atherosclerosis 
caused by endothelial dysfunction in areas of disturbed flow, even in the case of 
hypercholesterolemia. 
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Figure 6. Liposome delivery did not change lipid metabolism as measured by total 
serum cholesterol and triglycerides. This result supports the conclusion that PREY-
targeted delivery of BH4 to atheroprone arteries reduces atherosclerosis by rescuing 
endothelial dysfunction and is not an effect of altered lipid metabolism. 
CONCLUSIONS 
To improve endothelial function caused by disturbed flow I targeted uncoupled nitric 
oxide synthase by delivering BH4 as a candidate drug. PREY-targeted liposomes were 
shown to overcome known delivery barriers for BH4 by stabilizing BH4 in serum, and 
delivering BH4 to target tissue. BH4 delivery was shown to reduce vascular superoxide 
in the ligated artery of C57/BL6J mice, and improve endothelium dependent relaxation 
and reduce plaque formation in the ligated artery of ApoE-/- mice. Our results indicate 
that PREY-targeted nanocarrier delivery of BH4 could be used as a prophylactic 
treatment for atherosclerosis. 
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CHAPTER V 
 
THESIS CONCLUSIONS AND FUTURE PERSPECTIVES  
 
INTRODUCTION 
Arterial geometry affects the blood flow profiles in the cardiovascular system. In straight, 
unbranched vascular segments blood flow is unidirectional and laminar and time 
average wall shear stress due to viscous drag is high. In contrast, at branch points, sites 
of curvature and distal to stenoses blood flow becomes disturbed. Such regions can 
display flow separation, vortical shedding and low and oscillatory shear stresses [67]. 
The vascular endothelium is in direct contact with flowing blood and displays 
remarkable plasticity in response to varying shear stresses [75]. In the setting of 
unidirectional laminar shear stress, endothelial cells elongate and align in the direction 
of flow and develop an anti-inflammatory and anti-thrombotic phenotype [65]. These 
effects are associated with acute changes in endothelial cell signaling and marked 
changes in gene expression over the long term [75, 124]. As examples, in response to 
laminar unidirectional shear endothelial cells increase nitric oxide (NO), and endothelial 
nitric oxide synthase (eNOS), and exhibit decreases in inflammatory mediators [10]. In 
contrast, endothelial cells exposed to disturbed flow do not align and elongate, and 
become pro-inflammatory and pro-thrombotic. This phenotype is associated with 
sustained activation of pro-inflammatory signals with increased expression of 
inflammatory mediators including vascular cell adhesion molecule-1, intracellular 
adhesion molecule-1 and chemokines such as the monocyte chemoattractant peptide-1 
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[65, 74, 125-127]. The changes in endothelial cell phenotype caused by disturbed flow 
predispose these regions to local lipid deposition, inflammation and the focal 
development of atherosclerosis. Thus, atherosclerotic lesions predominantly occur at 
sites known to have disturbed flow such as branch points, the proximal coronary 
arteries and the distal aorta [48, 125, 126]. 
Most current treatments for atherosclerosis focus on correcting systemic risk factors 
such as hyperlipidemia, hypertension and diabetes. None of these therapies completely 
prevent cardiovascular events resulting from atherosclerosis. As an example, HMG Co-
A reductase inhibitors reduce cardiovascular events by approximately 40 to 50% 
indicating that there are residual risks that persist after lipid lowering [146, 147]. One 
explanation of this residual risk is that current treatments do not target vasculature that 
is atheroprone. Such regions might require a local dose of drug not achieved by 
systemic administration. 
Nanocarriers are an attractive platform for targeting therapy to regions of the circulation 
at risk for atherosclerosis. Nanoparticles can be functionalized to home to specific 
vascular regions affected by inflammation, lipid accumulation or oxidative injury, and 
can be used to deliver either therapeutic or imaging agents. Previously, nanoparticles 
have been used that target inflamed endothelium, inflammatory cells, the low-density 
lipoprotein receptor, thrombi and platelet aggregates [174-181]. While these studies 
have set a precedent for nanoparticle delivery to atherosclerosis, they depend on the 
presence of lesions formed after the initiation of the disease.  
In the present study, I sought to develop a novel nanotherapy to target atheroprone 
regions of the circulation prior to atherosclerotic lesion development. Given the marked 
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differences in gene expression and protein content of endothelial cells exposed to 
varying flow profiles, I reasoned that there might be differences in peptide binding to the 
surface of cells exposed to disturbed versus unidirectional laminar shear. Using 
combinatorial phage display, I identified peptides that preferentially accumulate in an 
area of disturbed flow created by partial carotid occlusion in mice. A candidate peptide 
identified in this screen was used to functionalize liposomal nanocarriers. Subsequent 
studies proved that these nanocarriers also targeted regions of disturbed flow and could 
be used to deliver effective anti-atherosclerotic therapy to these regions. 
CONCLUSIONS 
Atherosclerotic lesions develop when focal endothelial dysfunction caused by disturbed 
flow is compounded by systemic risk factors such as hypercholesterolemia. Targeted 
drug delivery to areas of disturbed flow is a promising approach to prevent 
atherosclerosis before lesions develop. Because prediction of these atheroprone areas 
is speculative, programming nanocarrier functions to navigate to and detect atheroprone 
areas is but unmet need. To accomplish this, I first developed a method to target 
atheroprone vasculature by in vivo phage display. I discovered four peptides that 
selectively target atheroprone vasculature. A candidate peptide, PREY was used to 
form targeted liposomal nanocarriers, which were observed to accumulate in areas of 
disturbed flow in vivo. I also showed that the PREY-targeted liposomes home to 
endothelial cells in atheroprone vasculature, making this nanocarrier a promising 
candidate to treat endothelial dysfunction. To improve endothelial function caused by 
disturbed flow I targeted uncoupled nitric oxide synthase by delivering BH4 as a 
candidate drug. PREY-targeted liposomes were shown to overcome known delivery 
barriers for BH4 by stabilizing BH4 in serum, and delivering BH4 to target tissue. BH4 
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delivery was shown to reduce vascular superoxide in the ligated artery of C57/BL6J 
mice and improve endothelial function and reduce plaque formation in the ligated artery 
of ApoE-/- mice. 
FUTURE PERSPECTIVES 
There are numerous druggable targets available for the treatment of cardiovascular 
disease, and almost all can benefit from targeted delivery [257, 258]. Therefore, 
additional studies could also test the delivery of alternative therapies, such as 
antioxidants. Clinical trials with nonspecific antioxidants have not shown benefit, and in 
some cases harm [259, 260]. A key oversight in a nonspecific antioxidant approach is 
that ROS play important physiological roles in cell signaling, innate immunity, hormone 
biosynthesis, and inflammation. To effectively oxidative stress with broad-spectrum 
antioxidants, a targeted approach that eliminates disease-causing ROS without 
disturbing physiological ROS signaling is essential [261]. Therefore, PREY-targeted 
nanocarriers could be utilized to deliver antioxidants, or inhibitors of ROS sources such 
as small molecule NOX inhibitors in a site-specific manner. Targeted approaches would 
also benefit inhibition of pathologic lipid metabolism and anti-inflammatory drugs such 
as dexamethasone. Delivery of therapeutic macromolecules such as peptides and RNA 
interference molecules such as siRNA and microRNAs are garnering increased 
acceptance as therapeutics due to advances in RNA delivery using synthetic 
nanoparticles [237, 262, 263]. Recent reports also demonstrate that high density 
lipoprotein (HDL) is able to carry microRNAs, and could be a useful therapeutic for 
cardiovascular disease [264]. Targeting these types of nanoparticles using peptides like 
PREY could be a useful strategy to prevent development of atherosclerosis.  
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In addition to allowing nanoparticle drug delivery, peptides like PREY may be useful for 
diagnostic imaging to define new risk factors for cardiovascular disease such as the 
number and location of areas of atheroprone vasculature. As a first step to investigate 
the use of PREY-targeted nanoparticles as a diagnostic platform, I would create 
targeted MRI contrast agents by incorporation of Gadolinium (III) chelates in the lipid 
membrane of PREY-targeted liposomes. MRI is an attractive platform because it is 
widely used in the clinic for diagnosis of cardiovascular pathologies by techniques such 
as angiography. Gadolinium chelates are commonly used in MRI imaging, and since its 
approval for clinical use in 1988, around 30% of MRI procedures use gadolinium 
chelates as contrast agents [265]. “Theranositc,” liposomes have been utilized for dual 
delivery of therapeutics and gadolinium chelates [266]. Other nanoparticle systems, 
such as USPIOs could also be used for MRI imaging of atheroprone vasculature by 
utilizing PREY-targeting. An alternative to MRI imaging would be positron emission 
tomography (PET). This approach offers increased sensitivity over MRI approaches, 
however, is much more expensive, the radioactive probes required have limited shelf 
lives and require specialized equipment to produce, and PET is much less common in 
clinical application. Ultrasound is a more attractive methodology because its use in 
cardiology is widespread, and PREY peptides could be used to target ultrasound 
contrast agents such as microbubbles [267]. Another attractive theranositc platform is 
HDL, or recombinant HDL. Studies have shown that HDL is a versatile naturally 
occurring nanoparticle, and can be loaded with imaging agents, therapeutics, and has 
naturally beneficial effects in the context of atherosclerosis [268-271].  
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Finally, this thesis demonstrates an exciting new possibility for drug targeting to 
pathological stimuli rather than symptoms of disease and sets a precedent for 
expanding the availability of biomarkers for preventative treatments. 
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